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Project Summary 
Capacitation is the process that renders spermatozoa competent for fertilization. Part of 
the process of capacitation is hyperactivation.Hyperactivation is a type of motility 
acquired by sperm in the female reproductive tractand it’s main characteristicis high 
flagellar bend amplitude and asymmetrical beating of the tail. The resulting swimming 
style, which is erratic and often non-progressive, is required for the infiltration of the 
cumulus oophorus, the penetration of zona pellucida and successful in vivo fertilization. 
Several clinical studies in human suggest that inhibition of hyperactivated motility is 
linked to male infertility in vivo and in vitro. The whole induction of hyperactivation is 
calcium dependent and is accompanied by a cascade of biochemical and physiological 
changes. Protein phosphorylation represents a very important aspect of hyperactivation, 
as it is one of the cells regulatory mechanisms to control various processes. Addition or 
removal of phosphate groups from serine, threonine or tyrosine residues is one of the 
most common mechanisms for regulating protein activity. In this project, for the first 
time we report the discovery of O-GlcNAc and O-GlcNAcylation as a novel form of 
post-translational modification in human sperm. Furthermore by using Computer 
Assisted Semen Analysis (CASA) for the monitoring of sperm hyperactivation, along 
with highly potent inhibitors of O-GlcNAcylation, Idiscovered impaired 
hyperactivation, after induction of O-GlcNAcylation during capacitation of human 
sperm. All of the motility experiments were followed by protein analysis,which 
revealed that a time-dependent decrease in O-GlcNAcylation occurs during 
capacitation. Since mature spermatozoa are highly compartmentalized, terminally 
differentiated and specialized cells, post-translational modifications play a huge role in 
the regulation of protein function. The discovery of a novel modification in human 
sperm, which effects hyperactivation, will give us mechanistic insights of the control of 
hyperactivation. 
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Chapter 1: General Introduction 
1.1 Spermatogenesis 
Spermatogenesis is the process by which male Primordial Germ Cells (PGCs) undergo 
meiosis and develop to mature spermatozoa(figure 1-1)(Avarbock et al., 1996). PGCs 
originate from the yolk sac (extra embryonic endoderm) and migrate into the genital 
ridges(Kierszenbaum, 2002).  
1.1.1 Location 
Production of the sperm cell takes place within several structures of the male 
reproductive system. The seminiferous tubules of the testes are the starting point of the 
process. The cells gradually migrate to the epididymis where the maturation process 
occurs(de Kretser et al., 1998a). Mature cells (sperm cells) are stored in the epididymis 
until ejaculation.  The whole process for humans takes approximately 64 days (Heller 
and Clermont, 1963) and is regulated by endocrine and paracrine systems. Histone 
modification and DNA methylation are implicated in the regulation of this process(Song 
et al., 2011, Baarends et al., 1999). 
1.1.2 Stages 
The whole process is comprised of two major steps. The first step is spermato-
cytogenesis, in which diploid primordial germ cellslocated in the basal compartment of 
seminiferous tubules undergo mitosis and give rise to two primary spermatocytes. PGCs 
continuously renew their population by mitotic replication (de Kretser et al., 1998b). 
Each primary spermatocyte then moves into adluminal compartment of the seminiferous 
tubules and undergoes meiosis to produce two haploid primary spermatocytes, which 
later on will divide into spermatids. In the second step of the process, spermiogenesis, 
the spermatids develop and give rise to mature sperm cells. Spermiogenesis is a series 
of events.  
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The changes include: 
1. Formation of sperm flagella(Inaba, 2011) 
2. Polymerization of tubulin and formation of microtubules(Bergen and Borisy, 
1980) 
3. Chromatin condensation in the nucleus(Brewer et al., 2002) 
4. Migration of the nucleus to the periphery of the cell(Foster et al., 2005) 
5. Formation of the acrosome(Abou-Haila and Tulsiani, 2000) 
6. Phagocytosis of the cytoplasm by the Sertoli cell and formation of the residual 
body (de Kretser et al., 1998b). 
 
Figure 1-1 The above figure describes the organisation and the basic steps of the process of spermatogenesis. 
The whole process is comprised of two major steps, spermatocytogenesis and spermiogenesis.  Primordial 
germ cells located in the seminiferous tubules undergo spermatogenesis and give rise to mature sperm cells 
that are stored in the epididymis (Avarbock et al., 1996).  
1.1.3 Regulation 
Neuroendocrine cells in the hypothalamus stimulate the pituitary gland by pulsatile 
secretion of gonadotropin releasing hormone (GnRH). The GnRH after is released into 
the portal blood system, binds to specific membrane receptors in the gonadotropic cells 
of the anterior pituitary. The pituitary gland gets stimulated and releases pulses of LH 
and a continuous stream of FSH to the peripheral blood (Blache et al., 2000). The role 
of the above two gonadotropins (glycoprotein hormones), FSH and LH are very 
important in the regulation of the production of spermatozoa in the testis(Leung and 
 9 
Steele, 1992). They share similar chemical and structural features. Both glyco-hormones 
are composed of similar α-subunit, but the β-subunit has unique sequence for each 
hormone. The pulses of LH that are released into the blood stream cause the stimulation 
of Leydig cells and production of testosterone and other androgens. The testosterone is 
converted into dihydro-testosterone (DHT) and estrogen, necessary for spermatid 
maturation. 
1.1.4 PTM during spermatogenesis and epididymal maturation 
The development of functional spermatozoa is accompanied by carefully orchestrated 
changes, controlled by independent regulatory mechanisms in distinct subcellular 
compartments. Tyrosine phosphorylation is one of these changes in protein function that 
has been recognized as an important component of sperm differentiation. cAMP-
induced tyrosine phosphorylation cascade has been studied in depth during the post-
ejaculatory events leading up to fertilization but little is known about the role of this 
pathway during spermatogenesis and epididymal maturation. Tyrosine phosphorylation 
becomes detectable by thetime sperm cellsenter the epididymis. Spermatozoa in the 
cauda epididymis express tyrosine phosphorylated residues initially in the principal 
piece and subsequently in the midpiece. By the end of these series of maturation events, 
cells exhibit a cAMP tyrosine phosphorylation response that runs the entire length of 
the tail from neck to the end-piece. The cAMP-dependent phosphorylation pattern in the 
presence of extracellular calcium is positively correlated with their capacity to exhibit 
hyperactivated movementand acquisition of functional competence(Lin et al., 2006). 
1.2 Sperm Structure 
The male gamete (spermatozoon), is a highly specialized and compartmentalized, nearly 
cytoplasm-free cell with a very important role(Barratt et al., 2009). It is specifically 
designed to travel through the cervix of the female reproductive tract, through the uterus 
and up to the fallopian tube, where it will fertilize the egg. During differentiation 
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spermatozoon forfeits most of its cytoplasm and organelles to transform into a motile 
cell capable of travelling in the female reproductive tract. The stripped-down 
spermatozoon contributes with many ways to the fertilization. It’s not only the paternal 
chromosomes that are being transferred to the egg but also the centrosome, perinuclear 
material and messenger RNA (mRNA). The spermatozoon is composed of a sperm head 
and a sperm tail (flagellum) (figure 1-2).  
  
Figure 1-2 The human spermatozoon is spatula shaped and consists of 3 major compartments, a 
head, a midpiece and a tail. The figure contains a detailed structured analysis of the sperm (Ward 
and Coffey, 1991). 
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1.2.1 Sperm Head 
In humans the head of the sperm is spatula-shaped. It is composed of a nucleus 
surrounded by cytoplasm. The nucleus is surrounded by a reduced nuclear envelope as 
the nuclear pore complexes have been removed during spermiogenesis. The reduced 
envelope covers the haploid genome, which is very condensed and most of the histones 
(~80%) are replaced by protamines. Protamine’s are arginine rich proteins essential for 
sperm head DNA condensation and stabilization (Balhorn, 2007). “Perinuclear matrix” 
is a structure that covers and offers protection to nucleus. It consists of disulfide bond-
stabilized proteins amalgamated with other proteins, which have a bivalent role(Oko, 
1995, Oko and Maravei, 1995). As long as the proteins remain in the complex of the 
Perinuclear Matrix, their only role is to protect the nucleus. After fertilization occurs, 
and the proteins are released into the oocyte cytoplasm they function as transcription 
factors(Sutovsky et al., 2003). 
1.2.1.1 Structure of the Perinuclear Matrix: 
1. Sub-acrosomal Layer: Functions to anchor the chromosomes 
2. Equatorial Segment: It carries several receptor molecules necessary for the 
initial binding of the sperm to oolemma (egg plasma membrane)(Barratt and 
Publicover, 2001), which occurs when the spermatozoon reaches the 
perivitelline space, after the penetration through the cumulus oophorus and the 
Zona Pellucida (ZP)(Toshimori et al., 1992). 
3. Post-acrosomal sheath: Carries several signalingproteins, which are released into 
the egg cytoplasm, after fusion of the egg with the sperm. The proteins disperse 
across the ooplasm and trigger signaling pathways responsible for the oocyte 
activation and initiation of the zygotic development(Sutovsky et al., 2003). 
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1.2.2 Sperm Flagellum 
The sperm tail (flagellum) consists of 4 different segments that share a common inner 
structure of the microtubules but differ in the external substructure. 
1.2.2.1 Inner Structure: 
The axoneme of sperm tail consists of a 9+2 arrangement of microtubules. 9 pairs of 
symmetrically arranged doublets of microtubules connected by dynein arms surround a 
central pair of microtubules. The microtubules of each doublet are connected each other 
by nexin links(Bozkurt and Woolley, 1993). The peripheral doublets are connected with 
the central pair by radial spokes(Smith and Yang, 2004, Goodenough and Heuser, 1985, 
Witman et al., 1978). Nine outer-dense fibers in parallel position with the outer doublets 
provide flexible, yet firm support during flagellar movement. The outer-dense fibers 
consist of serine, proline, and cysteine-rich filament proteins, abundant in zinc-
dependent disulfide cross bridging. 
1.2.2.2 Segments of the sperm tail (figure 1-3): 
1) Connecting Piece: The connecting piece, in most mammals (except rodents), 
contains the sperm proximal centriole inside the dense mass of capitulum. The 
capitulum is caged inside 9-segmented columns that are a direct continuation of 
the outer dense fibers in the other flagellar segments. 
2) Midpiece: Midpiece contains all the organelles, which generate the necessary 
energy for sperm flagellar motility. Approximately 75-100 mitochondria form 
the mitochondrialsheath, which covers the midpiece. Sperm mitochondria have 
unique characteristics. They possess protein isoforms or proteins that are 
apparently unique and they are not found in the somatic cell mitochondria. Due 
to high levels of mutagenic oxidative stress encountered by the spermatozoon, 
all the paternal mitochondria are eliminated by targeted proteolysis inside the 
fertilized ovum (Sutovsky et al., 2004). 
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3) Principal piece: The principal piece makes up ~2/3 of the length of the sperm 
flagellum. The fibrous sheath covers it.Fibrous sheath is a unique structure 
surrounding the outer dense fibers and the axoneme and is composed of two 
longitudinal columns running parallel to outer dense fibers 3 and 8.Its unique 
structure defines the shape of flagellar beat, the degree of flagellar flexibility 
and the plane of flagellar motion. Most of the proteins isolated from the mouse 
fibrous sheath contain anchoring sites for cAMP-dependent kinases, necessary 
for the process of sperm capacitation and hyperactivation prior to fertilization. 
A-kinase anchoring proteins represent in some species more than 50% of the 
fibrous sheath mass(Eddy et al., 2003). 
4) End Piece: Contains axonemal doublets and the ends of outer dense fibers and 
fibrous sheath. 
 
Figure 1-3 The flagellum consists of 4 different segments. The connecting piece located between the head and 
the midpiece (not shown in the figure), the midpiece, the principal piece and the endpiece (Ward and Coffey, 
1991) 
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1.2.3 Post-translational modifications of microtubules 
Microtubules perform multiple diverse functions including, regulation of cell shape, 
intra-cellular transport and cell motility. Post-translational modifications of tubulin 
subunits modify the outer and inner surfaces of microtubules providing a mechanism for 
their functional specialization. Tubulin PTMs that occur on microtubules and have been 
well characterized include acetylation of lysine residues, de-tyrosination, glycosylation 
and glutamylation. The use of antibodies that specifically recognize post-translationally 
modified tubulins reveals differences in the level of PTMs among distinct microtubules, 
or even along the length of the same microtubule which crucially affects their dynamics 
and organization (Laurent and Fleury, 1993, Wloga and Gaertig, 2010). 
1.2.4 Relationship between functional quality and protein tyrosine phosphorylation 
Human semen consists of a heterogeneous cell population with varying degrees of 
maturation and fertilizing capacity. Protein tyrosine phosphorylation has been 
associated with certain aspects of sperm physiology such as capacitation, acrosome 
reaction and hyper-activation (Visconti and Kopf, 1998). Buffone et al. (2004) 
demonstrated that the subpopulation of sperm isolated between the 45 and 65% of a 
45:65:90% Percoll gradient showed a clear impairment capacity to undergo protein 
tyrosine phosphorylation. Moreover the same population exhibited the lowest 
percentage of motile and morphologically normal sperm. The reduced capacity to 
undergo tyrosine phosphorylation could be the result from defects at the plasma 
membrane originated during spermatogenesis or epididymal maturation. Ollero et al. 
(2000) reported differences in the sperm membrane lipid composition and particular in 
the content of docosahexaenoic acid and cholesterol of sperm isolated from a similar 
gradient. Also work form the same group demonstrated that spermatozoa from 
varicocele samples (patients with decreased testicular function) presented a decreased 
response to the capacitating challenge, showing significantly lower motility, hyper-
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activation, incidence and intensity of tyrosine phosphorylation, and membrane 
fluidity(Buffone et al., 2006).The significance of the above lies in the association 
between structure and functional competence between spermatozoa (Ollero et al., 2000, 
Buffone et al., 2004). 
1.3 Controls Of Sperm Motility 
In order to achieve in vivo fertilization, sperm must be able to swim from their point of 
deposition to the oviductal ampulla (site of fertilization). Sperm’s ability to swim is 
progressively acquired during the epididymal transit.Later on, extrinsic factors secreted 
by the female genital tract, will trigger capacitation including hyperactivated motility, 
which is characterized by high flagellar bend amplitude and asymmetrical beating of the 
tail. Induction of hyperactivated motility is crucial for the sperm to achieve fertilization, 
because it is required for the penetration of the zona pellucida. 
1.3.1 Structure and role of dynein arms 
The axoneme is the core structure responsible for motility. Dynein arms, that connect 
the symmetrically arranged doublets, are responsible for the conversion of chemical 
energy (ATP) into mechanical energy required for sperm motility. They consist of three 
classes of subunits: 
1) Heavy chains: They contain ATPase activity and are responsible for the active 
sliding across the microtubule 
2) Intermediate Chains: They are responsible for the anchoring of the arms to the 
microtubules 
3) Light Chains: Regulatory function with Calcium binding properties that are 
required for the fine tuning of the microtubule sliding and the regulation of 
sperm motility(Inaba, 2002).  
The two-dynein arms have separate roles and unique functions. The outer dynein arms 
are bound to tubulin by the dynein-docking complex and their removal causes the 
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reduction of the flagellar beat frequency(DiBella and King, 2001, Porter and Sale, 2000, 
Takada et al., 2002). They produce as much as four/fifths of the force for flagellar 
movement and it contains three dynein heavy chain proteins, two intermediate and 
several light chains. The dynein-docking complex (DDC) is necessary for the binding of 
the outer dynein arm on the axonemal apparatus. On the other hand the inner dynein 
arms consist of three different classes, equally distributed along the microtubule and 
they determine flagellar wave form and beating symmetry(Brokaw and Kamiya, 1987). 
1.3.2 Dynein Regulatory complex (DRC) 
The DRC is a key regulator of motor activity and is bound to the inner dynein arms and 
functions as a scaffold for enzymes that regulate and modify dynein activity. 
Microtubules are cylindrical polymers, made up of polymerized a- and b- tubulin 
dimers. The dimers are often subjected to post-translational modifications, for example 
acetylation, palmitylation, phosphorylation, polyglutamylation and polyglycation, 
which are important for axonemal motility (Gagnon et al., 1996, Huitorel et al., 2002, 
MacRae, 1997). 
1.3.3 Regulation of dynein arms 
Recent genetic and proteomic studies have discovered several new components of 
axoneme, which are correlated with the generation, and regulation of sperm motility 
during fertilization. All these components have been well conserved through evolution. 
The initiation of movement begins with an activating stimulus, such as changes in ionic 
conditions or specific substances from eggs or the genital tract, followed by signaling 
conducted by a second messenger such as cAMP, cGMP or Ca2+which leads to 
axonemal movement through activation of axonemal dyneins by protein 
phosphorylation or de-phosphorylation(Morisawa, 1994, Cosson et al., 2008, Chang and 
Suarez, 2010). The mechanism of dynein activation has not been fully elucidated, but 
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the phosphorylation of the Tctex-2-related Light Chain (LC) of outer arm dynein and 
the de-phosphorylation of an Intermediate Chain of inner arm dynein appears to be a 
prerequisite for the activation of outer or inner arm dynein, respectively (Inaba et al., 
1998, Inaba et al., 1999, Nomura et al., 2000, Hozumi et al., 2008). 
1.4 Capacitation 
 
Capacitation is a combination of early and late events that renders spermatozoa 
competent for fertilization. The difference between the early and late events is that the 
fast processes do not require the addition of cholesterol acceptors such as BSA. Over 
the years capacitation has been associated with a list of endpoints.  
1. Initiation of motility (early event). 
2. Increase of cholesterol availability for acceptors (early event). 
3. Tyrosine phosphorylation increase (late event). 
4. The acquisition of the hyperactivated state, which is considered to be necessary 
for fertilization (late event). 
5. Preparation of the sperm to undergo an agonist induced acrosome reaction (late 
event). 
6. Employment of Chemo taxis (late event) (Eisenbach, 1999). 
1.5 Molecular basis of capacitation 
 
Although more than 50 years have passed since the process of capacitation was 
discovered (Austin, 1951, Chang, 1951) and several pathways have been characterized, 
the molecular basis of capacitation remains elusive (figure 1-4). 
1.5.1 Early Events 
 
Capacitation is a bicarbonate dependent process (Lee and Storey, 1986, Boatman and 
Robbins, 1991, Shi and Roldan, 1995, Gadella and Harrison, 2000, Visconti et al., 
2002). After ejaculation, in the female reproductive tract, the concentration of 
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bicarbonate in the sperm-surrounding milieu is significantly increased. Most of the 
bicarbonate enters the sperm through a sodium/bicarbonate co-transporter (Demarco et 
al., 2003, Romero and Boron, 1999). The movement of the bicarbonate inside the cell 
induces an increase in intracellular pH (Zeng et al., 1996) and has been associated with 
the regulation of cAMP metabolism by stimulating soluble Adenylyl Cyclase (sAC) 
(Bianchini et al., 1990, Garbers et al., 1982). Sperm from sAC deficient mice are not 
able to capacitate and consequently are infertile (Esposito et al., 2004). Moreover 
addition of sAC specific inhibitor stops capacitation (early and late events) (Hess et al., 
2005). The rise of intracellular cAMP activates Protein Kinase A, which phosphorylates 
various proteins, causing the initiation of several signaling pathways (Harrison and 
Miller, 2000, Harrison, 2004) and finally the initiation of sperm motility. In sperm 
exposed to bicarbonate, cAMP rises to a maximum within 60sec and the observed 
increase in PKA-dependent phosphorylation begins within 90sec (Salicioni et al., 2007). 
The pathway is very conserved in spermatozoa and has been identified in all 
mammalian species (Aitken et al., 1995, Visconti et al., 1995a, Visconti et al., 1995b, 
Galantino-Homer et al., 1997, Mahony and Gwathmey, 1999, Lewis and Aitken, 2001). 
PKA catalyzes the addition of the phosphate group to serine and threonine residues.  
The fact that it’s not a tyrosine kinase, suggests that, a protein kinase cascade regulates 
the process of capacitation. PKA also directly modulates the response of CatSper 
(voltage gated Calcium channel) to changes in membrane potential (Wennemuth et al., 
2003), causes the activation of phospholipids scramblase (Harrison, 1996, Harrison et 
al., 1996) and increases the availability of  cholesterol for external acceptors (Flesch et 
al., 2001). 
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Figure 1-4: The figure contains the biochemical pathways, which regulate early and late events of capacitation. 
The difference between early and late events is that late events require the presence of cholesterol acceptors  
1.5.2 Late Events 
 
Interestingly, both early and late events are centrally regulated by the 
bicarbonate/sAC/cAMP/PKA pathway, however late events are not instantly stimulated 
and require the presence of cholesterol acceptors. 
The cholesterol acceptors produce an enhanced K+ permeability (increased K+efflux), 
resulting in hyper-polarization of the membrane potential. The mechanism involved is 
not clear at present. One possibility is that cholesterol efflux redistributes or disrupts 
lipid rafts, resulting in changes in the activity of ion-selective channels.Hyper-
polarization regulates the ability of the sperm to generate transient intracellular Ca2+ 
elevation during an agonist induced acrosome reaction. So the changes in membrane 
potential are converted into a Ca2+ signal. It has been shown that in absence of BSA the 
changes in membrane potential do not occur and the sperm is unable to undergo an 
agonist induced acrosome reaction (Demarco et al., 2003). 
The report from (Morgan et al., 2008) tries to elucidate the paradox of a centrally 
regulated pathway, by producing a model that allows the dissection of PKA regulated 
events in sperm. This Group introduced a point mutation in the ATP binding site of the 
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PKA catalytic subunit “making room” for the oversized kinase inhibitors that compete 
ATP for binding. The large substituted inhibitors do not fit in the binding-site of wild-
type kinases and therefore would not affect other cellular processes. By incubating with 
oversized inhibitors they blocked of PKA phosphorylation of substrates, which occurs 
within 90sec of addition of bicarbonate and as well tyrosine phosphorylation. Blocking 
of tyrosine phosphorylation was only observed, when mutant sperm was incubated for 
an extended period of time. This came to the conclusion that PKA during capacitation 
plays two independent roles in the regulation of sperm motility. A fast role that is 
required for the activation of flagellar beat and a slow role that is required for the 
acquisition of the hyperactivated state (Morgan et al., 2008). 
Except for PKA, only a few kinases have been described in mature mammalian sperm 
using antibodies and the identity and functions and their targets in sperm are not well 
defined. Some of these kinases are: 
1. Protein Kinase C (PKC) (Rotem et al., 1990a, Rotem et al., 1990b) 
2. GSK3 (Vijayaraghavan et al., 2000) 
3. Casein Kinase II (Chaudhry et al., 1991a, Chaudhry et al., 1991b) 
4. Testis Specific Serine Kinase (TSSK) (Hao et al., 2004) 
Less is known about the tyrosine kinases that mediate the effect of the capacitation-
associated increase in protein tyrosine phosphorylation. Some evidence exist for the 
presence of: 
1. C-yes (Leclerc and Goupil, 2002) 
2. Src (Baker et al., 2006) 
3. ZRK (tyrosine kinase receptor) (Burks et al., 1995) 
The presence of csk in mouse sperm is particularly interesting. This kinase negatively 
regulates src kinase activity and it is at the same time directly inhibited by PKA, 
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opening the possibility that this pathway is involved in the regulation of the 
capacitation-associated increase in tyrosine phosphorylation(Baker et al., 2006). 
1.6 Journey in the female Oviduct 
After ejaculation the spermatozoa have to travel from the point of deposition to the 
oviductal ampulla, which is the point of fertilization, if ovulation occurs. It is an 
arduous journey that begins with the passage of the sperm through the ejaculatory 
ducts(Barratt and Cooke, 1991).The sperm mixes with fluid derived from the seminal 
vesicles, the prostate and the bulbourethral glands to form the semen(Kvist, 1991). In 
humans seminal fluid contains several components besides spermatozoa, all necessary 
for promoting the survival of spermatozoa and provide a nutritive and protective 
medium in which they can swim. 
1.6.1 Uterus and oviductal barriers 
In order for the spermatozoa to reach the site of fertilization, oviduct ampulla, they have 
to pass through many barriers in the uterus and oviduct. Cervical mucus is the first 
barrier for spermatozoa transportation, which contributes to important functions of 
sperm cells. The composition of the cervical mucus varies during the menstrual cycle. 
During the peri-ovulatory period, the mucus being produced by the cervical glands is 
more hydrate than other times of the menstrual cycle (Morales et al., 1993). Four 
parameters determine the penetration of spermatozoa through the mucus: 
1) The motility of spermatozoa 
2) The number of spermatozoa 
3) The amount of hydrolytic enzymes present in seminal plasma 
4) Contractility of the female reproductive tract. 
So only sperm cells that move rapidly (hyperactivated), with sufficient velocity in a 
forward progressive manner will traverse the cervix(Hanson and Overstreet, 1981). 
Hanson also found that the time from insemination until fertilization to occur can be as 
 22 
low as 30 minutes (Hanson and Overstreet, 1981). The same study suggests that the 
mucus present at the uterine-tubal junction or UTJ is rich in glycoproteins, which 
induce the deprivation of seminal macromolecules from spermatozoa surface. It is also 
reported that the mucus of the uterine tubal junction flows in the opposite direction to 
sperm movement, which may represent an additional system by which poor quality 
sperm is being filtered(Pacey et al., 1995, Kervancioglu et al., 1994, Baillie et al., 
1997). 
1.6.2 Effect and importance of human cervical mucus and bicarbonate on human 
sperm motion- hyperactivation 
During migration through the mucus, spermatozoa experience complex biophysical, 
biochemical and morphological interactions affecting their motion (Katz et al., 1989). 
All these events are of primary importance for their fertilizing capacity. Especially the 
induction of cAMP dependent tyrosine phosphorylation by bicarbonate, which leads to 
sperm hyperactivation confers several advantages to spermatozoa, including the 
development of forces necessary to detach the sperm head from epithelial adherence, 
the prevention of entrapment within confined spaces and the generation of increased 
forces to promote the penetration of cumulus and zona (Tesarik et al., 1990, Suarez et 
al., 1991). Zhu et al. (1992) by examining the effects of exposure to human cervical 
mucus indicated that mucus promotes hyperactivated motility but spermatozoa had 
different motility characteristics compared to control samples incubated in capacitating 
media. The difference maybe is related with a different phosphorylation induced-pattern 
by the media (mucus or capacitating media).   
Although the mechanism by which cervical mucus interacts with spermatozoa still 
remains unclear, it has been suggested that sperm transport through cervical mucus 
physically distorts the sperm structure and the physical contact results in macromolecule 
relocation on sperm proteins attached to plasma membrane (Yudin et al., 1989, Katz et 
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al., 1989). Here I have to say, that changes in cervical mucus properties and bicarbonate 
(HCO3 − ) secretion within the female reproductive tract, are critically linked to 
capacitation but they are 2 different things. Both HCO3− and mucus change 
dramatically throughout the menstrual cycle, but they change independently. 
1.6.3 Sperm Chemotaxis 
Until now, only two sources of sperm chemo-attractants have been identified. One is the 
mature oocyte and the other is the cumulus cells surrounding the oocyte (Sun et al., 
2005). No chemo-attractants have been identified in the cervical mucus. Progesterone is 
the main chemo-attractantsecreted by the cumulus cells along with atril natriuretic 
peptide (ANP) and other specific odorants(Zamir et al., 1993, Spehr et al., 2003). The 
identity of the chemo-attractants secreted by the oocyte, still remains unknown. 
1.7 Fertilization Events 
1) Passage through the jelly-like matrix of the cumulus oophorus which 
surrounds the oocyte 
2) Specific binding to the zona pellucida, a glycoprotein capsule which coats 
the oocyte 
3) Exocytosis of acrosomal contents. A process which renders the sperm 
plasma membrane capable of interacting with the oolemma 
4) Penetration of the zona pellucida 
5) Binding and fusion with oolemma. 
1.8 Infertility 
According to the World Health Organization, infertility is a disease of the reproductive 
system defined by the failure to achieve a clinical pregnancy after 12 months of regular 
unprotected sexual intercourse (Cooper et al., 2010). Conception rates for “normal” 
fertile couples can be as high as 30% per month and approximately 85% within 1 year 
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(Spira, 1986, Ford et al., 2000, Thonneau et al., 1991). In every case that the above rates 
are reduced, we have to account this couple as an “infertile couple”.  
Male infertility is a diagnosisof relative impairment in male reproductive potential. 
Male infertility presents a particularly complex clinical problem. While the patient’s 
semen may seem to be the target for diagnostic and therapeutic interventions and 
analysis, a positive outcome is in fact manifested by another person, a mother, giving 
birth to a child. While infertility is relatively common, it is very difficult indeed to 
establish the relative contribution of the male partner, given the profound difficulties, 
which exist in the accurate diagnosis of male infertility. 
Most studies have used the conventional criteria of semen quality, promulgated by 
WHO.Although of great importance, these criteria are not evidence-based. They have 
limited diagnostic value (Irvine and Aitken, 1994) and a significant proportion of men 
with normal conventional criteria of semen quality will be infertile because of defects in 
sperm function (Aitken et al., 1982a, Aitken et al., 1991) while a significant number of 
men with abnormal semen quality will have normal sperm function (Aitken et al., 
1982b, Aitken, 1985). 
Nevertheless, one common theme to emerge is that, using the available diagnostic 
techniques; male factor infertility is, in many studies, the commonest single diagnostic 
category (Collins et al., 1983, Cates et al., 1985, Hull et al., 1985, Haxton and Black, 
1987, Randall and Templeton, 1991, Thonneau and Spira, 1991, Schmidt et al., 1995). 
Contributory male infertility factor is identified in almost 50% of infertile couples while 
it is the sole cause in 20-30% of infertile couples (Hull et al., 1985, Thonneau et al., 
1991). 
Despite of the huge importance very little is known about the factors that cause sperm 
dysfunction. Out limited understanding of these factors disabled us to develop drugs to 
cure male infertility. Therefore, patients with sperm dysfunction have to rely on 
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Assisted Reproductive Techniques (ART), which some of them, especially ICSI, have 
been associate with birth defects. So there is an urgent need in understanding sperm 
physiology first, and then develop drugs to cure sperm dysfunction or improve the 
fertilization capacity of the man in order to reduce the usage of ART.    
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1.9 O-GlcNAcylation 
O-GlcNAc is a single sugar (monosaccharide) found on both cytosolic and nuclear 
proteins. It is attached in a β-linkage (covalent attachment) on serine and threonine 
residues (hydroxyl-amino acids) during protein post-translational modification. The 
addition of O-GlcNAc is a reversible procedure. 
1.9.1 Historical Background 
O-GlcNAcylation was discovered 30 years ago and since then the number of proteins 
that are O-GlcNAc modified is increasing rapidly. Early studies conducted in viruses 
and plants, hinted the presence of O-GlcNAc as a linking sugar to hydroxyl-amino acids 
in proteins. O-GlcNAc was first shown to be a major form of intracellular glycosylation 
in murine lymphocytes in 1984. Theses studies used radioactivelylabelled UDP-Gal, 
which can be used to “tag” on O-GlcNAc residues. 2 years later, in 1986, O-GlcNAc 
modification was found to be abundant in the cytoplasm and in all subcellular 
organelles, except mitochondria. Since these early studies, O-GlcNAc has been reported 
on a large number of proteins. Today, 30 years after the discovery, studies make clear 
that O-GlcNAc modification is as abundant and dynamic as phosphorylation on many 
nuclear and cytoplasmic proteins. 
Since the sperm is a highly compartmentalized, nearly cytoplasm-free cell, 
transcriptionally and translationally inactive, the identification of the role of O-
GlcNAcylation in sperm and especially capacitation will help us elucidate the molecular 
pathways, which control the process of capacitation(Hart et al., 1989b, Torres and Hart, 
1984b, Kreppel et al., 1997, Hart, 1997, Roquemore et al., 1994). 
1.9.2 Subcellular localization 
Studies using highly purified Glycosyltransferase and radioactively labelled sugar 
nucleotides (UDP-Gal) found that O-GlcNAc is abundant in the cytoplasm and in 
subcellular organelles with higher concentration found in the nuclear envelope (nuclear 
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pore proteins) and highest number in nucleoplasm. The first studies were conducted 
with murine lymphocytes 1984 (Torres and Hart, 1984a). In 1986 O-GlcNAc 
modification was found to be abundant in most of the subcellular organelles of rat liver, 
except mitochondria (Holt and Hart, 1986). Separate studies also found sites of O-
GlcNAc modification on polytene chromosomes of Drosophila larvae with markedly 
increased concentrations at inactive sites (Hart et al., 1989a).  This data suggest that the 
addition of O-GlcNAc not only affects proteins, by altering their function, but also 
DNA by specific silencing of gene expression.All the proteins that are O-GlcNAc 
modified can be phosphorylated and may contribute to the formation of multimeric 
complexes, a process often tightly regulated by phosphorylation(Hu et al., 2010). 
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1.9.3 Function and Structural analyses of enzymes involved in the O-
GlcNAcylation 
The dynamic turnover of O-GlcNAcylation occurs on Ser/Thr residues (figure 1-
5).Some of these residues can be phosphorylated, but whilst phosphorylation is 
mediated by over 500 kinases and 140 phosphatases (Manning et al., 2002), only two 
enzymes are responsible for O-GlcNAc cycling in Homo sapiens. These two enzymes 
are a Glycosyltransferase (OGT) and a glycoside hydrolase (OGA). OGT uses an 
activated sugar donor to drive the formation of the new glycosidic bond. Particularly 
OGT takes an a-linked UDP D-sugar to make a b-D glycosidic linkage to the side chain 
hydroxyls of serine or threonine residues.  
On the other hand, OGA takes the D-GlcNAc b-linked to serine/threonine and 
generates, through hydrolysis, b-D-GlcNAc as product(Martinez-Fleites et al., 2010). 
1.9.3.1 Structural Analysis of OGT 
 
OGT contains two domains, an N-terminal tetratricopeptide repeat (TPR) domain and a 
C-Terminal catalytic domain, which are separated by a bipartite nuclear localization 
sequence (NLS). TPR domains produce a super-helical structure containing an 
asparagine ladder that is critical for protein recognition. Alternative splicing produces 
multiple isoforms, each with varying umbers of TPRs. This difference allows each 
isoform to have a different behaviour on a vast array of tissues and on many different 
protein substrates (figure 1-6). In mammalian organisms OGT appears to be present as 
Figure 1-5 The schematic representation of addition and removal of O-GlcNAc. O-GlcNAcylation is 
described as the addition of a single sugar, O-GlcNAc on serine and threonine residues (Martinez-
Fleites et al., 2010). 
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three isoforms. The longest isoform is a nucleo-cytoplasmic OGT (ncOGT) with 12 
TPRs. A shorter form of OGT with 9 TPRs and an N-Terminal mitochondrion targeting 
sequence (mOGT) is mitochondrion specific. Finally an even shorter form of OGT, 
containing only 2 TPRs (sOGT), is found in the cytoplasm (Hanover et al., 2003).  
 
Figure 1-6 Schematic of OGT domain architecture with UDP bound. The catalytic lobes are shown in blue (N-
terminal) and orange C-terminal), and the TPR domains that cap the active site are in grey, and the 
transitional helix linking them to the catalytic domain is coloured purple and green (Lazarus et al., 2011).  
1.9.3.2 Structural Analysis of OGA 
Human OGA (hOGA) is a 92-kDa enzyme that consists of three domains linked by a 
disordered region. One N-terminal hydrolase catalytic domain (GH84 family) (orange), 
a C-terminal domain that has been reported to be a histone acetyltransferase (blue) and a 
stalk region (green) that is interrupted by a disordered region (grey)(figure 1-7).  
 
Figure 1-7 Schematic of OGA architecture. The hydrolase-catalytic domain is shown in orange, histone-
acetyltransferase in blue, stalk region in green and disordered region in grey(Vocadlo, 2012). 
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1.9.4 Biosynthetic pathway 
UDP-GlcNAc is the sugar-nucleotide donor for addition of O-GlcNAc to proteins. The 
synthesis of UDP-GlcNAc is a tightly regulated process. Between 2-5% of total glucose 
utilization is directed toward generating this sugar nucleotide (Hart et al., 1995). 
Between 2-5% of the fructose-6-phosphate formed is directed to the hexosamine 
biosynthetic pathway (HBP), in which UDP-GlcNAc is produced. The first step in HBP 
is catalysed by glutamine/fructose aminotransferase (GFAT). This step is important 
because it links the glycolytic metabolism to amino acid metabolism via the 
requirement of glutamine as the amide source. Also GFAT is a rate-limiting enzyme in 
this pathway. This enzyme is feedback inhibited by UDP-GlcNAc. Over-expression of 
GFAT leads in an increase in cellular UDP-GlcNAc, hyperinsulinemia and insulin 
resistance. The hexosamine core then is further modified through the addition of an 
acetyl group, linking this pathway to fatty acid oxidation (Love and Hanover, 2005). 
1.9.5 Regulation of glucose homeostasis 
From the first studies became rapidly clear that the addition of O-GlcNAc is 
developmentally important (Love et al., 2010). Perhaps the most persuasive evidence 
that the addition of O-GlcNAc is a dynamic post-translational modification comes from 
studies where cycling of O-GlcNAc has been blocked. These studies used soluble 
galactosyl transferase, an enzyme that caps O-GlcNAc with a galactose residue 
blocking recognition by hexosaminidases (OGA). Either overexpression of this enzyme, 
or microinjection into the cytosol, resulted in cell cycle arrest and apoptosis. Especially 
the group of Tak Mak blocked the murine glucosamine-6-phospate (EMeg32), which 
plays an emerging role in UDP-GlcNAc biosynthesis, and they noticed embryonic 
lethality at day7.5 and proliferative defect in mouse ES cells. Most of these defects can 
be ascribed to an impairment in the synthesis of the donor nucleotide-sugar UDP-
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GlcNAc, which leads in the lack of cytosolic and Golgi-driven glycosylation(Boehmelt 
et al., 2000b, Boehmelt et al., 2000a).  
1.9.6 Regulating protein phosphorylation and thus protein function 
O-GlcNAc addition occurs at serine and threonine residues, which can be also 
phosphorylated. Such evidence led to the hypothesis that we have a reciprocal 
relationship between O-GlcNAcylation and phosphorylation. 
 In order to investigate this hypothesis, it is necessary to measure the level of O-
GlcNAcylated proteins after extrinsic activation of phosphokinase and phosphatase and 
secondly after using PKC and PKA inhibitors. In the first attempt glycosylation of 
proteins was reduced and in the second was increased (Griffith and Schmitz, 1999). So 
the above data suggest that is a dynamic equilibrium between phosphorylation and O-
GlcNAcylation regarding the modification of serine/threonine residues. Cell signals 
leading to the production/activation of phosphokinases, change the balance of the 
equilibrium, giving greater control to phosphorylation by “suppressing” O-
GlcNAcylation. 
An example of this reciprocal relationship is RNA polymerase II. The C-terminal 
domain of polymerase consists of tandem repeats that can be either phosphorylated or 
glycosylated. In vivo experiments showed that the addition of a single residue of O-
GlcNAc blocked phosphorylation and the phosphorylation of residues inhibited 
glycosylation. The data suggest that this reciprocal relationship is necessary for the 
prevention of premature transcriptional initiation. The RNA pol II is hypo 
phosphorylated when it assembles and when the transcription is about to begin it gets 
hyper phosphorylated by the removal of O-GlcNAc (Conaway et al., 2000).   
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1.9.6.2 Interplay between O-GlcNAcylation and phosphorylation  
One of the main mechanisms that underlies the biological actions of O-GlcNAc 
involves its interplay with protein phosphorylation. Recent advances have allowed the 
full elucidation of the relationship between the above post-translational modifications. 
Until now, four different types of interaction have been identified (Fig 1-8)  
 
Figure 1-8Four different types of O-GlcNAc–phosphate crosstalk on protein substrates. A. 
Alternative and competitive occupancy B. Alternative and reciprocal occupancy at different sites C. 
Simultaneous occupancy at different sites D. Site dependent reciprocal or simultaneous occupancy 
(Zeidan and Hart, 2010) 
First, these modifications can competitively and alternatively occupy the same serine or 
threonine residue of a protein. Second, O-GlcNAc and phosphate can competitively and 
alternatively occupy different sites, which can be adjacent or distant. Third, they can 
simultaneously occupy different sites. In this case the balance between O-
GlcNAcylation and phosphorylation determines the function of the protein. Fourth, 
there can be complex crosstalk involving both site-specific alternative and simultaneous 
occupancy of O-GlcNAc and phosphate moieties. O-GlcNAc–phosphate crosstalk 
participates in nearly every biological aspect of protein function: changes in subcellular 
localization, protein turnover, enzymatic activity, and the DNA-binding and 
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transactivation properties of transcription factors. These changes in the activities of 
specific proteins play important roles in major cellular processes(Zeidan and Hart, 
2010). 
1.9.7 Altering protein degradation 
O-GlcNAc plays an emerging role in protein degradation in two ways. First by altering 
the targeting of some proteins to the proteasome and secondly by altering the activity of 
the proteasome itself. Some proteins contain domains that are rich in Proline, 
Glutamine, Serine and Threonine (PEST sequences). Phosphorylation events 
(activation) occurring on these residues trigger the protein degradation process. It is 
proposed, that the addition of O-GlcNAc, possibly blocks phosphorylation sites that 
regulate protein degradation. The main example is Oestrogen Receptor β (ERβ). In 
support of this data, mutation of the main sites of glycosylation results in protein with 
longer half-life than the wild-type (Cheng et al., 2000, Cheng and Hart, 2001). 
Oestrogen Receptor β plays a very important role in the development of several 
systems. Mice lacking ERβ have been generated with severe effects in bone and brain 
development. 
1.9.8 Adjusting the localization of proteins 
It was initially proposed that O-GlcNAc is an alternative NLS (Nuclear Localization 
Signal) because for some phospho-proteins such as c-Myc, Tau, Stat5a, Pax-6, ELF-1, 
Sp1, mTor, the nuclear forms were more O-GlcNAc modified than the cytoplasmic 
forms. The concept now is changed because after the examination of this model in 
C.elegans scientists found that nuclear transport of several transcription factors was 
normal despite the complete absence of O-GlcNAcylation due to OGT knockdown. So, 
if O-GlcNAc plays a role in nuclear localization, it may not be as a NLS signal but 
rather as a nuclear retention signal (Hanover et al., 2005). 
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1.9.9 Modulating protein-protein interactions 
The O-GlcNAcylation also modulates protein-protein interactions. The addition or 
removal of O-GlcNAc at specific residues affects the binding ability of the protein to 
other proteins in a positive or negative way. Three transcription factors, which are 
known to be affected, are Sp1, YY1, and ELF-2. Addition of O-GlcNAc may cause less 
effective binding of the protein to its targets. Alternatively addition of O-GlcNAc to 
Stat5a at Thr92 residue is necessary in order to induce gene transcription in response to 
prolactin stimulation (Juang et al., 2002, Hiromura et al., 2003, Gewinner et al., 2004). 
1.9.10 Mediating transcription 
O-GlcNAc modifies numerous transcription factors in respond to glucose/glucosamine 
concentration change causing up- or down-regulation in gene expression.  Typical 
example is Sp1 transcription factor (analysed below). 
1.10O-GlcNAcylation in sperm cell 
As discussed,O-GlcNAc modification has many interactions with phosphorylation, 
which plays a huge role by regulating a vast amount of signalling pathways during 
capacitation. Both occur in the nucleus and cytoplasm and both modify serine and 
threonine residues. Both modifications are dynamic processes that cycle on their protein 
substrates with a variable rate. The protein, the site of modification and cellular state 
determine the rate of phosphorylation or O-GlcNAcylation (Hart et al., 1995).  
This leads to the hypothesis that OGT and phosphokinases compete for the modification 
of the same residues and possibly the tightly regulated process of capacitation require 
the carefulorchestration of both modifications. 
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1.11 Objectives and research strategy 
• The aim of this work is to identify and understand the role of O-GlcNAc 
modified proteins during sperm capacitation  
• Provide an insight how O-GlcNAcylation effects the process of 
hyperactivation 
1.12 Project Hypothesis 
The main hypothesis of the project was that O-GlcNAcylation is heavily implicated and 
has a biological role in the process of sperm capacitation and especially hyperactivation. 
A series of experiments were carried out in order to elucidate the role of O-
GlcNAcylation 
• Western blot analysis, in an attempt to better understand how rapidly O-
GlcNAcylation changes during capacitation. 
• Modulation of stoichiometry by using small molecule inhibitors of OGA in 
order to study its function/effects in sperm capacitation 
• Complete motility analysis    
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Chapter 2: Materials and methods 
2.1 Introduction 
This chapter will give an overview of all the material used in the present study, as well 
as detailed protocols of all the methods employed. A brief outline of the experimental 
procedure followed in the figure below (figure 2-1). 
 
Figure 2-1:Flow chart showing the simplified experimental protocol used in the present study 
2.2 Sample Collection 
Semen was collected from healthy donors according to WHO (2010) criteria, taking part 
in the sperm donor program at Dundee University at Ninewells hospital. All donors 
gave informed consent that their spermatozoa would be used for research purposes only. 
Samples were produced by masturbation following by at least 2 days of sexual 
abstinence. The semen was allowed to undergo liquefaction at 37oC for 30min before 
further analysis. 
2.3 Discontinuous Gradient Centrifugation 
A 40%, 80% solution of Percoll in NCB was prepared. Firstly, 2ml of 80% was placed 
into a conical tube. Thereafter 2ml of 40% were carefully layered on top. 1ml of semen 
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was layered on top of the gradients, taking care in order not to mix the layers. The tube 
was centrifuged for 20min at 300x g. The centrifugation resulted into two distinct cell 
populations (fragments). The 40% fragment (Immature sperm) and the 80% fragment 
(mature sperm). The mature cells migrated to the bottom of the tube and formed a 
pellet, whereas the immature cells migrated between the 40% and 80% Percoll layers. 
The seminal plasma and debris remained in the top layer. After centrifugation the 
different layers were carefully removed to prevent any disturbances and mixing. The 
collected fractions were then washed with Non-Capacitating media to remove the 
Percoll and then they were re-suspended in the appropriate buffer. 
2.4 Capacitation  
Synthetic Tubal Fluid (STF) was used as media that supports capacitation. The media 
was composed of 4.7 mM KCl, 3 mM CaCl2, 1 mM MgSO4.7H2O, 106 mM NaCl, 5.6 
mM D-Glucose, 1.5 mM NaH2PO4, 1 mM Na pyruvate, 41.8 mM Na lactate, 25 mM 
NaHCO3, 1.33 mM Glycine, 0.68 mM Glutamine, 0.07 mM Taurine, Non-essential 
amino acids (1: 100 dilution in STF) and 30mg/ml BSA. Non-Capacitating Buffer 
(NCB) was adapted from STF excluding amino acids and NaHCO3. The components of 
NCB was 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4.7H2O, 116.4 mM NaCl, 5.6 
mM D-Glucose, 1.0 mM NaH2PO4, 2.7 mM Na pyruvate, 41.8 mM Na lactate and 25 
mM HEPES. The pH of NCB was adjusted to 7.4 with NaOH, and pH of STF was 
allowed to reach about 7.4 at 37°C and 5% CO2 before usage. The osmolality of the 
buffers were checked to be between 290-320 mOsm/kg. 
2.5 Motility Analysis 
The most common tool to study the sperm movement is high-speed video-micrography. 
Computer-aided semen analyzers (CASA) are based on image-analysis and by 
following the movement of the sperm head, can calculate parameters such as percentage 
of static/moving cells, flagellar beat frequency, surface of the flagellar beat envelope 
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and the maximal wave amplitude. 
A Hamilton Thorne ‘Ceros’ Computer Assisted Sperm analyzer(v12) was used for the 
assessment of sperm kinematics in all experiments. The analyzer uses negative phase 
contrast trinocular optics and a high-resolution CCD camera to determine the motility 
parameters. . The settings used for the instrument to detect human spermatozoa were: 60 
Hz; low and high size gates, 0.35 and 2.80, respectively; low and high intensity gate, 
0.5 and 2 respectively; minimum number of data points, 13; non-motile head size, 6 
pixels; non-motile head intensity, 160. The percentage of hyperactivated cells was 
assessed using standard criteria to identify hyperactivation; VCL ≥ 150 µm/s, linearity ≤ 
50%, and ALH ≥ 7 (Mortimer et al., 1998).These are figure 2-2: 
• Total motility (percentage of motile spermatozoa) will be used to report motility  
• Progressive motility (percentage of progressive motile cells)  
• Curvilinear velocity (VCL) (μm/s) (the time average velocity of sperm head 
along its actual curvilinear path, as perceived in two dimensions in the 
microscope)  
• Straight line velocity (VSL) (μm/s) (the time average velocity of sperm head 
along the straight line between its first detected position and its last)  
• Average path velocity (VAP) (μm/s) (the time average velocity of sperm head 
along its average path)  
• Amplitude of lateral head displacement (ALH) (μm/s) (the magnitude of lateral 
displacement of sperm head about its average path)  
• Linearity (LIN) (%) (The linearity of a curvilinear path)  
• Straightness (STR) (%) (Linearity of the average path)  
• Beat-cross frequency (BCF); (beats/second) average rate at which the sperm’s 
curvilinear path crosses its average path  
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• Rapid cells; the percentage of rapid moving cells,  
• Static cells; percentage of static/motion-less cells. 
Figure 2-2 Visual presentation of the parameters analyzed by CASA (Hinting et al., 1988). 
2.6 Procedure 
A Hamilton Thorne 2x-cell (20μm depth) microscope slide and a cover slip were pre-
warmed for two minutes on a Minitherm heated stage. 4μL of the sample was pipetted 
into each chamber and carefully covered with the pre-warmed cover slip in such a way 
to avoid drifting of the sample. To obtain representative measurement an approximate 
of 800 cells were assessed. The playback feature was used routinely to ensure that the 
majority of sperm cell were picked up, and that drift and the presence of round cell or 
debris were not biasing scan results. Once four lines of data, each comprising at least 
200 motile cells, were obtained then the slide was removed and washed. Data was 
transferred from CASA to a specifically designed Excel sheet, and manipulated from 
there. 
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2.7 Protein extraction/storing 
The sperm sample was centrifuged for 5 min in 17,000x g. After centrifugation, the 
sperm pellet was re-suspended in Laemmlesample buffer (no reducing agent) at the 
concentration of 0,25 million cells per μl (5 million cells into 20 μl) and the sample was 
heated at 950 C for 5 minutes. The insoluble material was removed from the sample by 
centrifugation (17,000x for 5 min). The sperm extract was stored at -20 or -80°C until 
ready for electrophoresis. 
Laemmle sample buffer recipe: 
• 0,5M Tris-HCl (pH=6.8) 
• 8% SDS (Sigma L4509) 
• 40% Glycerol (Sigma G5S16) 
• 0.008% bromophenol blue (Sigma B0126) 
2.8 Western blot analysis 
This procedure describes the technique by which sperm proteins can be identified on a 
solid support (nitrocellulose or PVDF membrane). Proteins are electrophoretically 
separated according to their molecular weight and transferred on a membrane where 
proteins will be detected using specific antibodies(Towbin et al., 1979). 
2.8.1 Gel preparation 
Firstthe glass plates have to be cleaned very thoroughly with regular soap and 
rinsedcarefully with water. Then the glasses have to be cleaned with 100% methanol or 
100% acetone, to remove any remaining soap. The system is assembled carefully before 
pouring the acrylamide solution (Mini-Protean Tetra system Bio-Rad). It is important to 
wear gloves to minimize fat from the hands and also acrylamide is a powerful 
neurotoxin.  
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Acrylamide solution was prepared and the TEMED and APS (catalysts) were added just 
before pouring the gel solution between the glass plates. This solution is called 
separating gel and different concentrations could be made according the protein size of 
interest (7.5- 15%). The volume necessary made for 1-2 slab gels is 5 ml.  
Separating Gel Recipe (10% acrylamide solution): 
• Water: 2,880 μL 
• Acrylamide: 1,500 μL 
• Tris-HCL (ph=8.8): 1,500 μL 
• SDS 20%: 30 μL 
• APS: 60 μL 
• TEMED: 6 μL 
Next we pour the gel solution using a Pasteur pipette and n-Butanol (water-saturated) is 
overlaid on the top of the gel (~100 μl). The limit of the top end (separating gel) is 
determined at 1 cm under the wells. The gel should polymerize in 10-20 min. We can 
determine when the polymerization is completed, by looking the extra gel left in the 
pipette or to see if the upper corners are rounded. Once the separating is polymerized, 
the stacking gel is overlaid on the top of the first gel and the comb was inserted after 
removing the Butanol layer. The thickness of the gel could change the volume needed, 
in this situation 0.75 mm is used.   
Stacking Gel Recipe (4% acrylamide solution): 
• Water: 3,125 μL 
• Acrylamide: 500 μL 
• Tris-HCL (pH=8.8): 1,250 μL 
• SDS 20%: 25 μL 
• APS: 50 μL 
• TEMED: 5 μL 
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2.8.2 Sample preparation 
The sample is prepared as following. Usually, the samples are frozen into 2X sample 
buffer.We warm the stock solution to be sure the SDS is not precipitated. The volume 
used per lane is usual 10-25 μl and Dithiothreitol (DTT) was used to reduce proteins. 
Before loading the samples, the wells can be washed with the running buffer (Tris-
Glycine-SDS) and the protein samples were heated at 95°C (3-5 min). The tank was 
filled with the 1X Tris-Glycine-SDSand the gel is running under constant current (20 
mA/gel, 200 V limit). 
Running buffer recipe (1L, 1x) 
• Trizma base (Sigma T1503): 3.03gr 
• Glycine (Sigma G8898): 14.4gr 
• SDS (Sigma L3771): 1gr 
2.8.3 Electrophoresis 
At the beginning the voltage is ~115 V, but after ~20 min the condition switch to 
voltage constant because the voltage reaches 200V and the migration is stopped when 
the dye front is close to get outside of the gel (approximately 1.5 h).  
2.8.4 Protein Transfer 
Next to the protein separation, the gel is carefully removed from the glass plates and 
soaks briefly in the transfer buffer. Therefore, gel is assembled in sandwich between 
Whatman 3M paper (2 pieces each side) including nitrocellulose (or PVDF) membrane. 
The membrane and pieces of paper was just the size of the gel (no extra) and the 
stacking gel is not usually kept for transfer. Importantly, the membrane must be at the 
positive side of the sandwich. When the transfer cassettes are in place in the tank filled 
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of transfer buffer the proteins are transferred for 2h at constant voltage (50V) for 2 
hours at room temperature with constant agitation (magnetic bar). 
Transfer buffer recipe (1L, 1x): 
• Trizma base (Sigma T1503): 3.03gr 
• Glycine (Sigma G8898): 14.4gr 
• Methanol (Sigma 179337): 20% 
2.8.5 Blocking and Incubation with the Primary antibody 
Once the transfer is completed the membrane is trimmed as the gel size if necessary and 
standard molecular weights are identified with a pen in case if during the incubation the 
staining is lost. At this point the membrane could be incubated in a blocking solution 
(5% milk powder in TBS-T) in a 50 ml falcon tube for an hour with constant agitation 
(rolling). Then, the membrane is rinsed with TBS-T and incubates at 4°C overnight with 
the primary antibody diluted in the blocking solution with constant agitation (rolling). 
2.8.6 Incubation with the secondary Antibody 
The next day, the membrane is washed 3 times with 5 ml of TBS-T for 10 minutes 
every time. The primary antibody bound to proteins is detectable by incubating the 
membrane with a secondary antibody conjugated to peroxidase (HRP-goat anti mouse 
or goat anti-rabbit). The secondary is incubated with the membrane for 60 min at room 
temperature. The same washes as for the primary antibody are performed in TBS-T.   
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Antibodies list: 
Ab raised against Species Isotype Company Concentrations 
1) O-GlcNAc Mouse mAb IgG1 Abcam –ab2739 1/250 
2) Anti-phosphotyrosine Mouse mAb IgG2 Millipore-16-452 1/1000 
3) β-actin Rabbit poly-clonal IgG Abcam –ab8227 1/1000 
4) Anti-mouse IgG HRP 
linked Horse IgG 
Cell Signaling♯ 
7076 1/500 
5) Anti-Rabbit IgG HRP 
linked Goat IgG 
Cell Signaling♯ 
7074 1/500 
Table 2-3: Description of the type and concentrations of the antibodies used in westerns  
 
2.8.7Visualization 
In the last step prepare a mixture of peroxidase and luminol (50-50) as a developer 
solution (1 ml) and pipet the solution directly on the membrane and leave for 5 minutes. 
After the 5 minutes we transfer the membrane in the blot holder and wipe any liquid left 
with a paper towel. Liquid must not come into contact with the film. In the processor 
room place the film over the blot starting with 1 minute and 5 minutes of exposure. 
2.9 Densitometry 
Image J was used to compare the density (intensity) of the bands of the western blot. A 
flatbed scanner was first used to scan the x-ray film. The method used is described in 
the ImageJ documentation. 
2.10 Statistical analysis 
Sperm motility data were analyzed using the independent Student t- test. Motility data 
are presented as mean ± standard error of the mean (SEM). The significance level was 
set as p<0.05.  
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Chapter 3: Study of O-GlcNAcylation during capacitation 
3.1 Introduction 
Mammalian sperm are unable to fertilize the oocyte immediately after ejaculation but 
they must undergo a cascade of biochemical and physiological changes that facilitates 
the development of the fertilization competent state. Spermatozoa during capacitation 
modify their motility pattern from a progressive state to a hyper-activated state. 
Progressive state is characterized by high flagellar beat frequency with low bend angle 
of the tail. On the other hand, hyper-activated state involves deep flagellar bends, due to 
increased flexure of the mid-piece and a decreased beat frequency resulting in greater 
lateral displacement of the head. Acquisition of the hyper-activated state by the 
spermatozoa has been reported for all eutherian spermatozoa (Suarez and Osman, 1987) 
and is essential for the effective penetration of the cervical mucus and penetration of the 
outer layers of the oocytes, leading to a successful fertilization. Not all the molecular 
mechanisms and signal transduction pathways involved are clearly known and 
understood, but various studies have shown that pH(Parrish et al., 1989) and cAMP are 
important regulatory components (Marquez and Suarez, 2007). Numerous studies also 
report the role of other PTMs like tyrosine/serine/threonine phosphorylation in human 
sperm capacitation but nothing has been ever reported about the involvement of O-
GlcNAcylation as a possible regulator of capacitation. In this part of the project, we 
have used anti-O-GlcNAc antibody (RL2) in human sperm, to detect proteins that serve 
as substrates for OGT. We report multiple sets of O-GlcNAcylated proteins in the 
molecular weight range of 25kDato 250kDa. The O-GlcNAcylation levels appear to be 
decreasing during the capacitation process. This fact suggests a vital role of O-GlcNAc 
modification for the acquisition of the hyper-activated state, which may involves the 
dynamic interaction between O-GlcNAcylation and ser/thr phosphorylation.  
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3.2Results 
In our attempt to identify and understand the role of O-GlcNAc modification and how 
rapidly changes during capacitation,a time-course experiment was performed. Due to 
high amount of sperm protein required in each lane in order to detect the modification, 3 
individual donor samples were pooled into one sample. The 80% fragment was isolated 
and incubated under capacitating conditions for 4h. At the time-points of 0h, 0.5h, 1h, 
2h, 4h protein was extracted and subjected to Western blotting. Protein analysis for 3 
different antibodies was performed. The first antibody is a RL2 (anti-O-GlcNAc 
antibody). The second antibody is an anti-phosphotyrosine antibody. Tyrosine 
phosphorylation is the most commonly used marker, in order to evaluate the progress of 
capacitation. Finally β-actin antibody was used as a loading control (figure 3-1). 
 
 
 
 
 
 
Figure 3-1: Time-course of protein O-GlcNAc levels in ejaculated human sperm under conditions that 
support capacitation. At the times listed, sperm proteins were extracted and subjected to SDS-PAGE 
immuno-blotting with an anti-O-GlcNAc monoclonal antibody. Three individual donor samples have 
been pooled in order to perform the above experiment. The results show that O-GlcNAcylation levels 
decrease during capacitation. Tyrosine phosphorylation increases during the same time period, 
revealing that the process of capacitation is progressing normally. Finally the level of b-actin remains 
stable (loading control) 
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The results reveal that O-GlcNAcylation levels decrease markedly following 
capacitation. There was a time-dependent decrease in O-GlcNAcylation of a subset of 
proteins of Mr =40-250 kDa.  
Discussion 
In the study presented, several O-GlcNAc proteins were identified, with the most 
prominent migrating at Mr=40-250kDa. The level of O-GlcNAcylation appears to 
decrease markedly following capacitation (Figure 3-1). Un-capacitated sperm 
demonstrated a high level of O-GlcNAcylation on Serine/Threonine residues compared 
with sperm that were incubated for 4h in capacitating media containing bicarbonate. As 
shown in Figure 3-1, when sperm were incubated for various periods of time between 0 
and 4h in media that supports capacitation, there was a time-dependent decrease in O-
GlcNAcylation of a subset of proteins of Mr =40-250kDa.While two immune-reactive 
bands appeared under all conditions (40 and 70kDa), the remaining bands detected with 
the anti-O-GlcNAc antibody appeared to be modified in a time-dependent manner. 
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Chapter 4: Inhibition of O-GlcNAcylation under capacitating conditions 
4.1 Introduction 
Sperm dysfunction is the single most common cause of infertility and accordingly to the 
most recent studies affects 1 in 15 men (HFEA 2005, www.hfea.gov.uk). Very little is 
known about the factors that cause sperm dysfunction due to lack of understanding of 
sperm physiology. Therefore, in order to develop drugs to cure male infertility, there is 
an urgent need to develop drugs capable of improving the fertilization capacity of the 
man in order to minimize the usage of ART, especially ICSI. ICSI treatment has been 
associated with birth defects and the use of it, has been increased dramatically, while 
the proportion of patients diagnosed with male factor, is stable(Davies et al., 2012, 
Oehninger, 2011, Jain and Gupta, 2007). Elucidating the sperm physiology will allow 
us to overcome the obstacle of ART and develop less invasive treatments. Sperm cells 
have no endoplasmic reticulum and minimal amount of cytoplasm and highly compact 
genetic material and they are transcriptionally and translationally inactive. Therefore 
control of cellular processes has to rely on modifying and changing activity of already 
existing proteins or enzymes. The O-GlcNAc modification is found on many sperm 
proteins, and addition and removal, can occur multiple times during the lifetime of a 
protein, imparting possible dynamic signaling properties to O-GlcNAc. Moreover, the 
interplay of O-GlcNAcylation and phosphorylation gives O-GlcNAc the potential to be 
involved in many cellular processes. In this chapter I modulate the stoichiometry of O-
GlcNAcylation on proteins, in order to study its function/effects in sperm motility. One 
of the most direct approaches of increasing global O-GlcNAc levels is by using small-
molecule inhibitors of O-GlcNAcase (OGA). The use of inhibitors of OGA in a cellular 
context results in a time-dependent increase in O-GlcNAc-modified proteins due to the 
continued activity of OGT and the impeded action of OGA. Over 12 OGA inhibitors 
have been described to date (Macauley and Vocadlo, 2010). In this part of the project 
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we examine the effects of 3 different OGA inhibitors (PUGNAc, Thiamet-G, 
GlcNAcstatin) and one OGT inhibitor(4Ac5S-GlcNAc)in sperm motility. Inducing O-
GlcNAcylation with GlcNAcstatin (GNS) leads to lower hyperactivation levels (Sort3), 
Average Path Velocity (VAP), Linearity (LIN), Curvilinear velocity (VCL) and 
Amplitude of lateral head Displacement (ALH) in GNS. Treatment with Thiamet G 
reduces the percentage of progressive motile cells, hyperactivated cells (Sort3) and also 
reduces Linearity. Treatment with PUGNAc leads to lower hyperactivation levels (Sort 
3) and linearity.Finally treatment with 4Ac5s-GlcNAc, which is an OGT inhibitor 
significantly changes the percentage of progressive motile cells and Linearity. Western 
blots of the above specimens confirm the PTM induction/reduction in a protein level.  
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4.2 Methods 
The 80% fragment was isolated as described in Chapter 2. The sample was separated 
and incubated in capacitating media (STF) with DMSO (vehicle control) or the 
appropriate concentration of the inhibitor for 4h. At the end of the capacitating period 
motility measurements were taken, followed by protein extraction for western blot 
analysis. 
Drug Concentrations 
GlcNAcstatin 1μΜ 
Thiamet G 1μΜ 
PUGNAc 100μΜ 
4Ac5S-GlcNAc 10μM 
 
4.3 Motility Results 
In Chapter 3 the results revealed that O-GlcNAc is present in many sperm proteins 
(protein bands between 40-250 kDa) and is constantly decreasing when cells are 
incubated under capacitating conditions in presence of bicarbonate. In this part of the 
project I modulate the stoichiometry of O-GlcNAcylation, by using highly potent 
inhibitors, in order to study it’s effect on sperm motility, because hyper-activated state 
is regulated by a series of phosphorylation events and O-GlcNac is proven to interact 
with phosphorylation events in other cell types. 
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4.3.1 CASA motility analysisoverview  
The settings and conditions used to evaluate sperm motility parameters are all described 
in chapter 2.5. The total population of sperm cells can be divided into two sub-
populations, motile and static. The static-cell population consists of non-motile cells 
with minimum and maximum size values for movement as defined by CASA settings 
[for humans: 0.35(min) - 2.8(max)]. The comparison of the static cell population 
between treated and untreated cells provides the necessary information about the 
toxicity of the compounds (drugs). Since there is no significant difference in all 
treatments (figure 4-1,7,13,19), no toxic effects can be attributed to the compounds used 
to treat the cells. The motile cell population can be further divided into 3 categories 
(rapid, medium, slow). Slow cells are defined as cells with either of the following 
attributes: VAP<VAP CUT-OFF=5μ/s or VSL<VSL CUT-OFF=11μ/s. Medium cells 
are moving with VAP: CUT-OFF(5μ/s)<VAP<PATH-VELOCITY(25μ/s). Finally 
rapid cells are moving with VAP>PATH-VELOCITY (25μ/s). No significant 
differences in all three cases were observed (figure 4-2,8,14,20). The next charts 
compare the percentage of progressive cells between treated and non-treated 
populations (figure 4-3,9,15,21). Progressive cell population is defined as cells moving 
with both VAP>PATH VELOCITY (25μ/s) and STR>80% as determined by values 
defined for humans in the ANALYSIS SETUP. No significant differences between the 
percentages of progressive cells in all three treatments. On the next two charts I 
compare the VAP and VSL values along with their frequency distributions.Only GNS 
reduced significantly VAP. No significant differences were observed in VSL (GNS 
treatment) and VAP, VSL (rest of the treatments) (figure 4-4,10,16,22). Next I compare 
the level of hyper-activated cells between treated and non-treated populations (figure 4-
5,11,17,23). Hyper-activated cells are cells defined as cells moving with both three 
parameters: VCL≥150μm/s, ALH≥7μm, LIN≤50. Only treatment with GNS causes 
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significant decrease in hyperactivation levels. Treatment with Thiamet G and PUGNAc 
causes a decrease in hyper-activation levels that appears not to be significant, probably 
due to small sample population. In my attempt to investigate which of the parameters of 
the hyper-activated cells is affected the most, I compared the average values of VCL, 
LIN and ALH along with their frequency distributions (figure 4-6,12,18,24). In every 
case, the amplitude of lateral head displacement was significantly decreased and the rest 
of the hyper-activation parameters remained unaffected for Thiamet G and PUGNAc. 
The average value of VCL was significantly decreased in GNS treatment.    
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4.4 Statistics 
4.4.1 Inhibitor: GNS  
10individual donor ejaculates (N=10) were examined. The data were first tested for 
normality with Shapiro-Wilk test. The Shapiro-Wilk test, proposed in 1965, calculates a 
W-Statistic that tests whether a random sample comes from a normal distribution. If the 
W statistic is significant, then the hypothesis that the respective distribution is normal 
should be rejected. The null hypothesis for this test is that the data are normally 
distributed. The Prob.<W value listed in the output (Table i) is the p-value. If the chosen 
alpha level is 0.05 and the p-value is less than 0.05, then the null hypothesis that the 
data are normally distributed is rejected. If the p-value is greater than 0.05, then the null 
hypothesis is not rejected.The software used, was Graphpad-Prism v6.0. Furthermore, 
since the data are continuous and we want to compare the differences between two 
treatments on the same sample, a paired T-test analysis was performed. Testing for 
normality is a prerequisite for the paired t-Test, as all the parametric tests require that 
the data are normally distributed.Complete motility analysis revealed, that induction of 
O-GlcNAcylation with GNS causes significant decrease in Average Path Velocity 
(VAP) p=0.0462, Curvilinear velocity (VCL) p=0.0030, hyperactivation levels (Sort3) 
p=0.0013, Linearity (LIN) p=0.0225 and Amplitude of lateral head displacement (ALH) 
p=0.0043. 
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Donor VAP VCL Sort3 LIN ALH DMSO GNS DMSO GNS DMSO GNS DMSO GNS DMSO GNS 
151 56.53 52.60 93.95 87.08 6.09 3.01 48.00 46.00 4.53 4.63 
218 71.05 73.20 113.85 116.73 10.68 9.43 53.25 54.50 4.38 4.55 
222 60.60 53.28 101.63 88.50 7.96 4.17 47.25 46.00 5.00 4.48 
227 71.43 67.05 116.38 108.50 13.06 9.19 54.00 52.75 4.68 4.43 
225 68.05 65.45 119.00 105.10 15.24 7.40 46.50 52.50 5.43 4.53 
214 88.53 79.88 130.60 114.38 11.10 8.46 59.00 62.75 4.80 4.08 
333 88.38 82.48 131.55 116.08 12.68 6.74 58.75 64.00 5.00 4.08 
180 99.35 92.98 151.25 127.38 21.39 7.44 60.00 68.25 5.10 4.18 
189 107.38 95.85 162.88 132.73 22.57 9.56 60.25 68.75 5.48 4.43 
239 88.00 95.85 138.78 137.43 19.39 10.41 57.25 66.50 5.03 4.73 
Shapiro-Wilk 
Normality test            
W 0.9438 0.9172 0.9792 0.9449 0.9455 0.9041 0.8617 0.8874 0.9575 0.909 
P-Value 0.5965 0.3342 0.9607 0.6083 0.6154 0.2429 0.0799 0.1584 0.7572 0.274 
Passed Normality 
Test (alpha=0.05)? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Average 79.93 75.86 125.99 113.39 14.02 7.58 54.43 58.20 4.94 4.41 
S.E.M. 5.33 5.16 6.77 5.34 1.76 0.76 1.73 2.81 0.11 0.07 
Paired T Test   0.0462   0.0030   0.0013   0.0225   0.0043   
Table i 
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4.4.2 Inhibitors: Thiamet G, PUGNAc, 4Ac5S-GlcNAc (4AC) 
7individual donor ejaculates (N=7) were examined. The data were first tested for 
normality with Shapiro-Wilk test. The software used, was Graphpad-Prism v6.0. Then a 
paired T-test analysis was performed.Complete motility analysis revealed, that 
induction of O-GlcNAcylation with Thiamet G causes significant decrease in 
Progressive motility p=0.0167, Hyperactivation levels (Sort3) p=0.0015 and Linearity 
(LIN) p=0.0027. Treatment with PUGNAc significantly decreased hyperactivation 
levels (Sort3) p=0.0086 and Linearity (LIN) p=0.0287. Finally treatment with 4AC 
significantly increased Progressive motility p=0.0093 and Linearity (LIN) p=0.0057.  
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Donor Progressive Sort3 LIN DMSO Thiamet G DMSO Thiamet G DMSO Thiamet G 
151 52.68 49.41 9.00 5.24 52.25 52.50 
214 63.18 68.37 11.10 8.56 59.00 62.00 
225 43.32 50.14 15.24 8.73 46.50 51.50 
333 64.24 68.14 12.68 10.89 58.75 61.75 
180 72.58 82.74 21.39 17.56 60.00 63.75 
189 72.96 83.74 22.57 15.24 60.25 64.50 
239 68.93 80.65 19.39 12.44 57.25 64.00 
Shapiro-Wilk normality test   
W 0.8896 0.851 0.9317 0.9771 0.7992 0.7577 
P value 0.2725 0.1256 0.5652 0.9444 0.1402 0.1253 
Passed normality test 
(alpha=0.05)? Yes Yes Yes Yes Yes Yes 
Average 62.56 69.03 15.91 11.24 56.29 60.00 
S.E.M. 4.14 5.52 2.00 1.60 1.93 2.10 
Paired T Test   0.0167   0.0015   0.0027            
Table ii 
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Donor Sort3 LIN DMSO PUGNAc DMSO PUGNAc 
151 9.00 5.95 52.25 51.75 
214 11.10 6.16 59.00 62.25 
225 15.24 6.92 46.50 53.50 
333 12.68 12.82 58.75 58.50 
180 21.39 16.04 60.00 62.25 
189 22.57 14.81 60.25 65.50 
239 19.39 17.51 57.25 61.00 
Shapiro-Wilk normality 
test   
W 0.9317 0.8545 0.7992 0.9202 
P value 0.5652 0.135 0.1402 0.4707 
Passed normality test 
(alpha=0.05)? Yes Yes Yes Yes 
Average 15.91 11.46 56.29 59.25 
S.E.M. 2.001724169 1.887572115 1.926806953 1.889822365 
Paired T Test   0.00867057   0.028723753          
Table iii 
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Donor Progressive LIN DMSO 4ac DMSO 4ac 
151 52.68 52.32 52.25 54.50 
214 63.18 67.16 59.00 61.25 
225 43.32 44.72 46.50 48.00 
333 64.24 69.76 58.75 60.25 
180 72.58 78.96 60.00 62.50 
189 72.96 82.18 60.25 67.00 
239 68.93 74.94 57.25 61.00 
Shapiro-Wilk normality test   
W 0.8896 0.9145 0.7992 0.9108 
P value 0.2725 0.4276 0.1402 0.4015 
Passed normality test (alpha=0.05)? Yes Yes Yes Yes 
Average 62.56 67.15 56.29 59.21 
S.E.M. 4.140465945 5.245469181 1.926806953 2.328925623 
Paired T Test   0.00932792   0.005714357  
 Table iv     
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4.5 Inhibitor 1: GlcNAcstatin (GNS)  
GlcNAcstatin is a competitive inhibitor of enzymes of the O-GlcNAcase family and 
binds directly to the O-GlcNAcase active site. This compound is able to raise O-
GlcNAc levels in human HEK 293 and SH-SY5Y neuro-blastoma cells lines and thus 
provides a novel and highly potent tool for the study of the role of the O-GlcNAc in 
intracellular signal transduction pathways (Dorfmueller et al., 2006, Macauley and 
Vocadlo, 2010). The concentration used, was 1μM and the cells were incubated under 
capacitating conditions for 4 hours. At the end of the capacitating period, motility 
measurements were taken.  
In the first chart (figure 4-1), I compare the static/motile cell population between treated 
and untreated cells. The static cell population consists of non-motile cells with size 
values defined by CASA. The CASA uses defined size values to avoid counting other 
cells types, that can be found in semen, such as white or red blood cells.  
 
 
 
 
p=0.625
p=0.714
010
2030
4050
6070
8090
100
Motile Static
Pe
rc
en
ta
ge
 o
f T
ot
al
 C
el
l c
ou
nt
DMSOGNS
Figure 4-1Influence of GNS treatment on human sperm motility. The histograms show that 
treatment with GNS doesn’t affect the percentage of the motile or static cell population. 
Values are mean ±SEM for 10 individual donor ejaculates. 
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The comparison of the static cell population between treated and untreated cells 
provides the necessary information about the toxicity of the compound. Since there is 
no significant difference, no toxic effects can be attributed to the compound used to 
treat the cells. 
In order to be more specific, the percentage of the static cell population in untreated 
cells was 11.64% vs. 12.53% in the treated population. The p-value was 0.714, so no 
significant difference can be attributed to the result. On the other hand, the motile cell 
population in untreated cells was 87.75% vs. 86.98% in the treated population. The p-
value was 0.625, so no significant difference can be attributed to the result. 
The motile cell population can be further divided into 3 categories (rapid, medium, 
slow). Slow cells are defined as cells with either of the following attributes: VAP<VAP 
CUT-OFF=5μ/s or VSL<VSL CUT-OFF=11μ/s. Medium cells are moving with VAP: 
CUT-OFF (5μ/s)<VAP<PATH-VELOCITY (25μ/s). Finally rapid cells are moving 
with VAP>PATH-VELOCITY (25μ/s).  
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Figure 4-2Influence of O-GlcNAcylation induction (GNS treatment) on the motile cell population. The 
histograms show that treatment with GNS doesn’t affect the percentage of the Rapid/medium/slow cell 
population. Values are mean ±SEM for 10 individual donor ejaculates 
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No significant differences in all three cases were observed (figure 4-2). 
The percentage of the rapid cell population in untreated cells was 93.21% vs. 92.28% in 
the treated population. The p-value was 0.503, so there is no significant difference. 
Next, the percentage of the medium cell population in untreated cells was 2.47% vs. 
3.14% in the treated population. The p-value was 0.132, so no significant difference can 
be attributed to the result. Finally, the percentage of the slow cell population in 
untreated cells was 4.31% vs. 4.57% in the treated population. The p-value was 0.413, 
so no significant difference can be attributed to the result. 
The next chart compares the percentage of progressive cells between treated and un-
treated populations (figure 4-3). Progressive cell population is defined as cells moving 
with both VAP>PATH VELOCITY (25μ/s) and STR>80% as determined by values 
defined for humans in the CASA ANALYSIS SETUP.   
Figure 4-3: Influence of O-GlcNAcylation induction (GNS treatment) on human sperm 
progressive motility. The histograms show that treatment with GNS doesn’t affect the 
percentage of the progressive cell population. Values are mean ±SEM for 10 individual donor 
ejaculates. 
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The percentage of progressive cells in the untreated population was 55.92% vs. 59.80% 
in the treated population. The p-value was 0.162, so no significant difference can be 
attributed to the result. 
 
On the next two charts I compare the VAP and VSL values. 
 
 
 
 
 
The average path velocity in untreated cells was 79.93 μm/sec and in treated cells was 
75.86 μm/sec. The p-value was 0.046, so treatment with GNS significantly reduces the 
average path velocity of the cells. The average progressive velocity in untreated cells 
was 65.99 μm/sec vs. 64.86 μm/sec in treated cells. The p-value was 0.551, so no 
significant difference can be attributed to the difference in VSL. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4: Influence of O-GlcNAcylation induction (GNS treatment) on human sperm path velocity (VAP) and 
progressive velocity (VSL). The histograms indicate, that treatment with GNS significantly decreases VAP but has no 
effects in VSL. Values are mean ±SEM for 10 individual donor ejaculates 
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In the next chart, I compare the level of hyper-activated cells between treated and un-
treated populations (figure 4-5). Hyper-activated cells are cells defined as cells moving 
with both three parameters: VCL≥150μm/s, ALH≥7μm, LIN≤50. 
 
 
 
 
 
In the un-treated population the percentage of hyper-activated cells was 14.02% vs. 
7.58% in the treated population. So treatment with GNS significantly reduces hyper-
activation levels. 
In my attempt to investigate which of the parameters of the hyper-activated cells is 
affected the most, I compared the average values of VCL, LIN and ALH 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5: Influence of O-GlcNAcylation induction (GNS treatment) on human sperm 
hyperactivation levels. The histogram shows, that treatment with GNS, significantly reduces 
the percentage of hyper-activated cells. Values are mean ±SEM for 10 individual donor 
ejaculates. 
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Treatment with GNS significantly affects all three parameters. The last result indicates 
that the lower hyper-activation levels measured in GNS treatment (figure 4-5) are the 
result of changes in all three parameters, which contribute to hyper-activation (figure 4-
6).  
 
 
 
 
 
 
Figure 4-6: Influence of O-GlcNAcylation induction (GNS treatment) on human sperm 
linearity levels (LIN), amplitude of lateral head displacement (ALH) and curvilinear velocity 
(VCL). The histograms show, that treatment with GNS, significantly increases LIN and 
decreases ALH and VCL. Values are mean ±SEM for 10 individual donor ejaculates. 
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4.6 Inhibitor 2: Thiamet G 
 
Thiamet G is a potent and selective inhibitor of O-GlcNAcase and demonstrates a Ki 
value of 21nM. It increases cellular O-GlcNAc modified proteins. Thiamet G is the first 
highly potent O-GlcNAcase inhibitor known to be orally bioavailable and effectively 
cross the blood brain barrier. 
The concentration used, was 1μM and the cells were incubated under capacitating 
conditions for 4 hours. At the end of the capacitating period, motility measurements 
were taken. 
In the first chart (figure 4-7), I compare the static/motile cell population between treated 
and untreated cells. The static cells population consists of non-motile cells with size 
values defined by CASA. The CASA uses defined size values to avoid counting other 
cells types that can be found in semen, such as white or red blood cells. 
 
Figure 4-7: Influence of Thiamet G treatment on human sperm motility. The histogram shows that treatment 
with Thiamet G has no effects in the motile or static cell population. Values are mean ±SEM for 7 individual 
donor ejaculates.  
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The comparison of the static cell population between treated and untreated cells (figure 
4-7) provides the necessary information about the toxicity of the compound. Since there 
is no significant difference, no toxic effects can be attributed to the compound used to 
treat the cells. 
In order to be more specific, the percentage of the static cell population in untreated 
cells was 6.80% vs. 6.32% in the treated population. The p-value was 0.609, so no 
significant difference can be attributed to the result. On the other hand, the motile cell 
population in untreated cells was 93.20% vs. 93.68% in the treated population. The p-
value was 0.689, so no significant difference can be attributed to the result(figure 4-7). 
The motile cell population can be further divided into 3 categories (rapid, medium, 
slow). Slow cells are defined as cells with either of the following attributes: VAP<VAP 
CUT-OFF=5μ/s or VSL<VSL CUT-OFF=11μ/s. Medium cells are moving with VAP: 
CUT-OFF (5μ/s)<VAP<PATH-VELOCITY (25μ/s). Finally rapid cells are moving 
with VAP>PATH-VELOCITY (25μ/s). 
 
 
 
Figure 4-8: Influence of O-GlcNAcylation induction (Thiamet G) on the motile cell population. The histogram 
shows that treatment with Thiamet G has no effects in the Rapid/medium/slow cell population. Values are 
mean ±SEM for 7 individual donor ejaculates.  
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No significant differences in all three cases were observed (figure 4-8).  
The percentage of the rapid cell population in untreated cells was 95.32% vs. 95.26% in 
the treated population. The p-value was 0.741, so there is no significant difference. 
Next, the percentage of the medium cell population in untreated cells was 1.76% vs. 
1.99% in the treated population. The p-value was 0.381, so no significant difference can 
be attributed to the result. Finally, the percentage of the slow cell population in 
untreated cells was 2.90% vs. 2.73% in the treated population. The p-value was 0.634, 
so no significant difference can be attributed to the result(figure 4-8). 
The next chart compares the percentage of progressive cells between treated and un-
treated populations (figure 4-9). Progressive cell population is defined as cells moving 
with both VAP>PATH VELOCITY (25μ/s) and STR>80% as determined by values 
defined for humans in the CASA ANALYSIS SETUP. 
 
 
 
Figure 4-9: Influence of O-GlcNAcylation induction (Thiamet G) on human sperm progressive motility. The 
histogram shows that treatment with Thiamet G has no effects in the progressive cell population. Values are 
mean ±SEM for 7 individual donor ejaculates.  
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The percentage of progressive cells in the untreated population was 62.56% vs. 69.03% 
in the treated population. The p-value was 0.166, so no significant difference can be 
attributed to the result (figure 4-9). 
 
On the next two charts I compare the VAP and VSL values (figure 4-10). 
 
 
 
Figure 4-10: Influence of O-GlcNAcylation induction (Thiamet G treatment) on human sperm path velocity 
(VAP) and progressive velocity (VSL). The histogram shows that treatment with Thiamet G has no effects in 
VAP or VSL. Values are mean ±SEM for 7 individual donor ejaculates  
 
The average path velocity in untreated cells was 86.29 μm/sec and in treated cells was 
85.59 μm/sec. The p-value was 0.776, so treatment with Thiamet G does not affect the 
average path velocity of the cells. The average progressive velocity in untreated cells 
was 71.94 μm/sec vs. 74.12 μm/sec in treated cells. The p-value was 0.092, so no 
significant difference can be attributed to the difference in VSL (figure 4-10). 
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In the next chart, I compare the level of hyper-activated cells between treated and un-
treated populations (figure 4-11). Hyper-activated cells are cells defined as cells moving 
with both three parameters: VCL≥150μm/s, ALH≥7μm, LIN≤50. 
 
 
Figure 4-11: Influence of O-GlcNAcylation induction (Thiamet G) on human sperm hyperactivation levels. 
The histogram shows that treatment with Thiamet G significantly decreases the percentage of hyper-activated 
cells. Values are mean ±SEM for 7 individual donor ejaculates. 
 
In the un-treated population the percentage of hyper-activated cells was 15.91% vs. 
11.24% in the treated population. So treatment with Thiamet G significantly reduces 
hyper-activation levels (figure 4-11). 
In my attempt to investigate which of the parameters of the hyper-activated cells is 
affected the most, I compared the average values of VCL, LIN and ALH (figure 4-12). 
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Figure 4-12: Influence of O-GlcNAcylation induction (Thiamet G treatment) on human sperm linearity levels 
(LIN), amplitude of lateral head displacement (ALH) and curvilinear velocity (VCL). The histogram shows 
that treatment with Thiamet G significantly increases LIN but has no effects in ALH and VCL. Values are 
mean ±SEM for 10 individual donor ejaculates. 
 
Treatment with Thiamet G significantly increases onlylinearity out of the three 
parameters that contribute to hyperactivation. So the significant reduction of hyper-
activation levels observed in figure 4-11, is the result of an increase in linearity. 
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4.7 Inhibitor 3: PUGNAc 
 
PUGNAc is a potent in vitro inhibitor of the enzyme responsible for the removal of O-
GlcNAc from proteins and can be used to increase O-GlcNAc levels on nuclear and 
cytoplasmic proteins in vivo. Studies have shown that PUGNAc approximately causes a 
2-fold increase in O-GlcNAc levels in the human colon cancer cells, HT29, although the 
effects on individual proteins varied. O-GlcNAc levels in other cell lines tested (NIH 
3T3, CV-1 and HeLa), were also affected by PUGNAc. At the concentration tested, 
PUGNAc is shown to be non-toxic for many cell lines (Haltiwanger et al., 1998, Park et 
al., 2005, Perreira et al., 2006, Shanmugasundaram et al., 2006). 
The concentration used, was 100μM and the cells were incubated under capacitating 
conditions for 4 hours. At the end of the capacitating period, motility measurements 
were taken. 
In the first chart (figure 4-13), I compare the static/motile cell population between 
treated and untreated cells. The static cells population consists of non-motile cells with 
size values defined by CASA. The CASA uses defined size values to avoid counting 
other cells types that can be found in semen, such as white or red blood cells. 
 
Figure 4-13: Influence of PUGNAc treatment on human sperm motility. The histogram shows that treatment 
with PUGNAc has no effects in the motile/static cell population. Values are mean ±SEM for 7 individual donor 
ejaculates.  
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The comparison of the static cell population between treated and untreated cells, 
provides the necessary information about the toxicity of the compound. Since there is 
no significant difference, no toxic effects can be attributed to the compound used to 
treat the cells (figure 4-13). 
In order to be more specific, the percentage of the static cell population in untreated 
cells was 6.80% vs. 8.1% in the treated population. The p-value was 0.369, so no 
significant difference can be attributed to the result. On the other hand, the motile cell 
population in untreated cells was 93.20% vs. 91.89% in the treated population. The p-
value was 0.444, so no significant difference can be attributed to the result (figure 4-13). 
The motile cell population can be further divided into 3 categories (rapid, medium, 
slow). Slow cells are defined as cells with either of the following attributes: VAP<VAP 
CUT-OFF=5μ/s or VSL<VSL CUT-OFF=11μ/s. Medium cells are moving with VAP: 
CUT-OFF (5μ/s)<VAP<PATH-VELOCITY (25μ/s). Finally rapid cells are moving 
with VAP>PATH-VELOCITY (25μ/s). 
Figure 4-14: Influence of O-GlcNAcylation induction (PUGNAc treatment) on the motile cell population. The 
histogram shows that treatment with PUGNAc has no effects in the Rapid/medium.slow cell population. 
Values are mean ±SEM for 7 individual donor ejaculates.
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No significant differences in all three cases were observed (figure 4-14). 
The percentage of the rapid cell population in untreated cells was 95.32% vs. 95.23% in 
the treated population. The p-value was 0.400, so there is no significant difference. 
Next, the percentage of the medium cell population in untreated cells was 1.76% vs. 
2.12% in the treated population. The p-value was 0.471, so no significant difference can 
be attributed to the result. Finally, the percentage of the slow cell population in 
untreated cells was 2.90% vs. 2.64% in the treated population. The p-value was 0.129, 
so no significant difference can be attributed to the result (figure 4-14). 
The next chart compares the percentage of progressive cells between treated and un-
treated populations (figure 4.15). Progressive cell population is defined as cells moving 
with both VAP>PATH VELOCITY (25μ/s) and STR>80% as determined by values 
defined for humans in the CASA ANALYSIS SETUP. 
 
 
Figure 4-15: Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm progressive 
motility. The histogram shows that PUGNAc treatment has no effects in the progressive cell population. 
Values are mean ±SEM for 7 individual donor ejaculates.  
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The percentage of progressive cells in the untreated population was 62.56% vs. 69.03% 
in the treated population. The p-value was 0.166, so no significant difference can be 
attributed to the result (figure 4-15). 
 
On the next two charts I compare the VAP and VSL values (figure 4-16). 
 
 
Figure 4-16: Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm path velocity 
(VAP) and progressive velocity (VSL). The histogram shows that PUGNAc treatment has no effects in VAP or 
VSL. Values are mean ±SEM for 7 individual donor ejaculates 
 
 
 
The average path velocity in untreated cells was 86.29 μm/sec and in treated cells was 
84.00 μm/sec. The p-value was 0.443, so treatment with PUGNAc does not affect the 
average path velocity of the cells. The average progressive velocity in untreated cells 
was 71.94 μm/sec vs. 72.20 μm/sec in treated cells. The p-value was 0.923, so no 
significant difference can be attributed to the difference in VSL (figure 4-16). 
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In the next chart, I compare the level of hyper-activated cells between treated and un-
treated populations (figure 4-17). Hyper-activated cells are cells defined as cells moving 
with both three parameters: VCL≥150μm/s, ALH≥7μm, LIN≤50. 
 
Figure 4-17: Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm hyperactivation 
levels. The histogram shows that treatment with PUGNAc significantly decreases hyper-activated cells. Values 
are mean ±SEM for 7 individual donor ejaculates. 
 
In the un-treated population the percentage of hyper-activated cells was 15.91% vs. 
11.46% in the treated population. So treatment with PUGNAc significantly reduces 
hyper-activation levels. 
In my attempt to investigate which of the parameters of the hyper-activated cells is 
affected the most, I compared the average values of VCL, LIN and ALH (figure 4-18). 
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Figure 4-18: Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm linearity levels 
(LIN), amplitude of lateral head displacement (ALH) and curvilinear velocity (VCL). The histograms show 
that PUGNAc treatment significantly increase LIN but has no effects in ALH and VCL. Values are mean 
±SEM for 10 individual donor ejaculates. 
 
 
Treatment with PUGNAc significantly increases only linearity out of the three 
parameters that contribute to hyperactivation. So the significant reduction of hyper-
activation levels observed in figure 4-17, is the result of an increase in linearity. 
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4.8 4Ac5S-GlcNAc 
4Ac5S-GlcNAc is an inhibitor of the O-GlcNAc transferase (OGT) and its inhibition 
causes a dramatic reduction in O-GlcNAc levels. 
The concentration used, was 10μM, and the cells were incubated under capacitating 
conditions for 4 hours. At the end of the capacitating period, motility measurements 
were taken. 
In the first chart (figure 4-18), I compare the static/motile cell population between 
treated and untreated cells. The static cells population consists of non-motile cells with 
size values defined by CASA. The CASA uses defined size values to avoid counting 
other cells types that can be found in semen, such as white or red blood cells 
 
Figure 4-19: Influence of 4Ac5S-GlcNAc treatment on human sperm motility. The histogram shows that 
4Ac5S-GlcNAc treatment has no effects in motile/static cell population. Values are mean ±SEM for 7 
individual donor ejaculates. 
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The comparison of the static cell population between treated and untreated cells 
provides the necessary information about the toxicity of the compound. Since there is 
no significant difference, no toxic effects can be attributed to the compound used to 
treat the cells (figure 4-18). 
In order to be more specific, the percentage of the static cell population in untreated 
cells was 6.80% vs. 6.46% in the treated population. The p-value was 0.582, so no 
significant difference can be attributed to the result. On the other hand, the motile cell 
population in untreated cells was 93.20% vs. 93.54% in the treated population. The p-
value was 0.582, so no significant difference can be attributed to the result(figure 4-18). 
The motile cell population can be further divided into 3 categories (rapid, medium, 
slow). Slow cells are defined as cells with either of the following attributes: VAP<VAP 
CUT-OFF=5μ/s or VSL<VSL CUT-OFF=11μ/s. Medium cells are moving with VAP: 
CUT-OFF (5μ/s)<VAP<PATH-VELOCITY (25μ/s). Finally rapid cells are moving 
with VAP>PATH-VELOCITY (25μ/s).  
Figure 4-20: Influence of 4Ac5S-GlcNAc treatment on the motile cell population. The histogram shows that 
4Ac5S-GlcNAc treatment doesn’t affect Rapid/medium/slow population. Values are mean ±SEM for 7 
individual donor ejaculates. 
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No significant differences in all three cases were observed (figure 4-19). 
The percentage of the rapid cell population in untreated cells was 95.32% vs. 95.65% in 
the treated population. The p-value was 0.524, so there is no significant difference. 
Next, the percentage of the medium cell population in untreated cells was 1.766% vs. 
1.764% in the treated population. The p-value was 0.991, so no significant difference 
can be attributed to the result. Finally, the percentage of the slow cell population in 
untreated cells was 2.90% vs. 2.57% in the treated population. The p-value was 0.373, 
so no significant difference can be attributed to the result(figure 4-19). 
The next chart compares the percentage of progressive cells between treated and un-
treated populations (figure 20). Progressive cell population is defined as cells moving 
with both VAP>PATH VELOCITY (25μ/s) and STR>80% as determined by values 
defined for humans in the CASA ANALYSIS SETUP.  
Figure 4-21: Influence of 4Ac5S-GlcNAc treatment on human sperm progressive motility. The histogram 
shows that 4Ac5S-GlcNAc treatment, has no effects in the progressive cell population. Values are mean ±SEM 
for 7 individual donor ejaculates. 
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The percentage of progressive cells in the untreated population was 62.56% vs. 67.15% 
in the treated population. The p-value was 0.009, so no significant difference can be 
attributed to the result (figure 4.20). 
 
On the next two charts I compare the VAP and VSL values. 
 
 
Figure 4-22: Influence of O-GlcNAcylation induction (4Ac5S-GlcNAc treatment) on human sperm path 
velocity (VAP) and progressive velocity (VSL). The histograms show that 4Ac5S-GlcNAc treatment has no 
effects in VAP or VSL. Values are mean ±SEM for 7 individual donor ejaculates 
 
The average path velocity in untreated cells was 86.29 μm/sec and in treated cells was 
87.54 μm/sec. The p-value was 0.766>0.05, so treatment with 4Ac5SGlcNAc does not 
affect the average path velocity of the cells. The average progressive velocity in 
untreated cells was 71.94 μm/sec vs. 74.68 μm/sec in treated cells. The p-value was 
0.452, so no significant difference can be attributed to the difference in VSL (figure 
4.21). 
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In the next chart (figure 4.22), I compare the level of hyper-activated cells between 
treated and un-treated populations (figure 4-8). Hyper-activated cells are cells defined 
as cells moving with both three parameters: VCL≥150μm/s, ALH≥7μm, LIN≤50.  
   
Figure 4-23: Influence of 4Ac5S-GlcNAc treatment on human sperm hyperactivation levels. The histograms 
show that 4Ac5S-GlcNAc treatment has no effects in the percentage of hyper-activated cells. Values are mean 
±SEM for 7 individual donor ejaculates.  
In the un-treated population the percentage of hyper-activated cells was 15.91% vs. 
12.92 % in the treated population. So treatment with 4Ac5SGlcNAc significantly 
reduces hyper-activation levels. 
In my attempt to investigate which of the parameters of the hyper-activated cells is 
affected the most, I compared the average values of VCL, LIN and ALH.       
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Figure 4-24: Influence of O-GlcNAcylation induction (4Ac5S-GlcNAc treatment) on human sperm linearity 
levels (LIN), amplitude of lateral head displacement (ALH) and curvilinear velocity (VCL). The histogram 
shows that treatment with 4Ac5S-GlcNAc significantly increases LIN, but has no effects in ALH and VCL. 
Values are mean ±SEM for 10 individual donor ejaculates. 
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4.8 Protein Results 
The aim of this part of the project is to detect changes in O-GlcNAcylation levels at a 
protein level caused by the inhibitors. From our motility results became apparent that 
GNS is the most potent inducer of O-GlcNAcylation, as significantly affected four 
sperm motility parameters (VAP, VCL, Hyper-activation, ALH). Four individual donor 
ejaculates were incubated under capacitating conditions with DMSO (vehicle control) 
and GNS (inhibitor). After a four-hour capacitation period, protein was extracted and 
analysed by Western blotting. One out of four donors expressed an increase in O-
GlcNAcylation levels (Donor 6), which was accompanied with an increase in tyrosine 
phosphorylation levels. This fact suggests that capacitation was normally progressing. 
One donor (Donor 4) expressed a small increase in O-GlcNAcylation levels. The 
tyrosine-phosphorylation for the same donor was slightly increased.Finally the O-
GlcNAcylation levels in the rest of the donors remained unchanged (figure 4-25).  
 
 
Figure 4-25: Influence of O-GlcNAcylation induction (GNS treatment) on human sperm protein O-
GlcNAcylation levels on 4 different donors.   
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In the next experiment (figure 4-26) one donor ejaculate was incubated under non-
capacitating conditions (NCB), capacitating conditions with the vehicle control 
(DMSO) and capacitating conditions with the three inhibitors (GNS, Thiamet G, 
PUGNAc). Our results reveal that incubation under capacitating conditions without 
inhibitors (STF) leads to a decrease in O-GlcNAcylation levels. This results come to an 
agreement with the results in Chapter 3. At the same time an increase in tyrosine 
phosphorylation levels was observed, fact that suggests capacitation is progressing 
normally. Capacitation with the three inhibitors, causes in every case an increase in O-
GlcNAcylation levels. Thiamet G appears to be the most potent inhibitor. 
Figure 4-26: Influence of O-GlcNAcylation induction (3 different inhibitors) on human sperm protein O-
GlcNAcylation levels.The results indicate that O-GlcNAcylation induction with GNS/Thiamet G or PUGNAc 
siginificantly increases the concentration of O-GLcNAcylated proteins. 
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4.9 Discussion 
In this part of the project, the effects of 4 different inhibitors in sperm motility were 
studied. The inhibitors are: GNS, Thiamet G, PUGNAc and 4Ac5S-GlcNAc. The first 3 
inhibitors block OGA, the enzyme responsible for the removal of O-GlcNAC, so the 
cells were submitted under conditions, which induce O-GlcNAcylation. 4Ac5S-GlcNAc 
blocks OGT, the enzyme responsible for the addition of O-GlcNAc to ser/thr residues, 
so it blocks O-GlcNAcylation in the cells.The results show that GNS,Thiamet G and 
PUGNAc significantly cause impaired hyper-activation. 4Ac5S-GlcNActreatments had 
no significant effects in hyperactivation levels. This can be explained by the fact that the 
cells were treated with relatively low concentration of the drug. Maybe gradual increase 
of the drug concentration will give significant results. Finally 4Ac5S-GlcNAc is a 
newly developed drug and little is known about its potency and it’s effect in sperm 
cells.   
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Chapter 5: General discussion 
It was 40 years ago, when Yanagimachi observed that hamster spermatozoa swimming 
in the oviduct exhibited a vigorous motility pattern which he named hyperactivation 
(Yanagimachi, 1970). Since then, hyperactivation has been the centre of vast amount of 
studies trying to extensively understand the physiological factors leading to 
hyperactivation, as acquisition of the hyperactivated state by the sperm is necessary for 
successful in vivo fertilization. Factors that inhibit the transition of sperm to a 
hyperactivated state are all related with infertility. 
Male factor infertility accounts for 35% (de Kretser, 1997) of all infertility cases 
worldwide and can be caused by various factors, including hormonal disorders, 
infections and anatomical disorders (Mosher and Pratt, 1991, de Kretser et al., 1998a). It 
is often associated with impaired sperm motility and morphology for which there is no 
specific therapeutic treatment. Currently, the only treatment available, for sub fertile 
men, are Assisted Reproduction Techniques (ART). It has come to light that the 
modification and expression of human sperm proteins play a crucial role in sperm 
function. The present study was designed to explore the molecular nature of sperm 
capacitation in order to find suitable treatment options for men suffering from infertility. 
This includes the identification of all post-translational modifications on sperm proteins, 
which can serve as potential targets for the development of biomarkers and the use of 
drugs to cure sperm dysfunction. 
Little is known about the mechanisms responsible for the transition of sperm into the 
hyper-activated state. Current evidence suggests that cAMP/PKA and Ca2+ signalling 
pathway are of paramount importance for the regulation of sperm motility (Suarez et al., 
1987, Lindemann and Goltz, 1988, Yanagimachi, 1994, Ho and Suarez, 2003). Also, 
other pathways have been characterized, such as G-protein mediated pathways 
implicated in sperm motility. Although, as we discussed, many factors are involved in 
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the acquisition of the hyper-activated state, in this study only the role of post-
translational modifications was my main area of study.  
Post-translational modifications play a very important role from the early stages of 
spermatogenesis to epididymal maturation and finally capacitation and acquisition of 
the capacity to fertilize. My aim was to identify if O-GlcNAcylation is present in sperm 
proteins and how is involved in the process of capacitation.  
In the first part of the study, several O-GlcNAc proteins were identified. Un-capacitated 
sperm was shown to exhibit a higher level of O-GlcNAcylationcompared with sperm 
that were incubated in capacitating media. Finally, the level of O-GlcNAcylation 
appeared to decrease markedly following capacitation.  
Interpretation of western blot results was a vital part of my project. Only by being aware 
of the limitations of the procedure, it is possible to correctly interpret the results. 
Western blotting is one of the most common procedures in biochemical labs. It 
separates proteins from a sample by size, then tests using antibodies to determine 
whether a given protein is present. Despite its popularity, Western blotting has several 
disadvantages. Western blots are non-quantitative. The results reveal, if a particular 
protein is present, but they do not make it possible to accurately quantify, how much of 
the protein is present. Moreover, the Molecular weight of a protein can only be 
estimated with western blotting, rather than determined precisely. Finally antibodies 
sometimes exhibit some off-target binding, which can make for poorer results. 
In the second part of the study, I used specific, highly potent inhibitors to induce O-
GlcNAcylation and examine its effects in the motility of spermatozoa.  
The activity of the O-GlcNAcase (OGA) was disrupted using the selective inhibitor, 
GlcNAcstatin. Currently, the GlcNAcstatins are the most potent OGA inhibitors 
available (Dorfmueller et al., 2009). They bind directly to the active site of OGA by 
hydrogen bonding, and induce global increases in O-GlcNAc levels. GlcNAcstatins 
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show a 100.000 times enhanced selectivity for O-GlcNAcase over human lysosomal 
hexosaminidases, an established concern over the commonly used O-GlcNAcase 
inhibitor, PUGNAc, making them better tool for reasearching the effects of induction of 
O-GlcNacylation. As additional verification, Thiamet G, an OGA inhibitor, structurally 
unrelated to GlcNAcstatin C was also used, to further test OGA inhibition. 
From the motility results became apparent that induction of O-GlcNAcylation 
significantly affects at least four sperm motility parameters, one of which is hyper-
activation. 
In order to understand the basis of the effects of O-GlcNAcylation, we have to come to 
a better understanding of capacitation and the core enzymes, which control it. 
Capacitation is a combination of early and late events that has been associated with a 
list of endpoints. Several pathways have been characterized, but the molecular basis of 
capacitation remains elusive. The main pathway starts from an increase in intracellular 
bicarbonate. The movement of the bicarbonate inside the cell induces an increase in 
intracellular pH, which stimulates soluble Adenylyl Cyclase. The rise of intracellular 
cAMP activates Protein Kinase A, which phosphorylates various proteins, causing the 
initiation of several signaling pathways. PKA refers to a family of ser/thr kinases whose 
activity is dependent on cellular levels of cAMP. Blocking PKA with specific inhibitors 
blocks the whole process of phosphorylation. So PKA is one of the core enzymes that 
control capacitation. Is it possible that O-GlcNAcylation is involved in the regulation of 
PKA? 
Francisco et al. demonstrated that induction of O-GlcNAc levels regulates the 
phosphorylation of some PKA substrates. More specifically, Western analysis in 
primary chicken forebrain neurons, revealed that the effect of increasing cAMP levels 
on the phosphorylation of PKA substrates was antagonized by increasing O-GlcNAc 
levels (Francisco et al., 2009). So their results provide a functional correlate to a 
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previous study demonstrating reciprocal relationship between O-GlcNAcylation and 
phosphorylation on neuronal cytoskeletal proteins downstream of cAMP-PKA signaling 
(Griffith and Schmitz, 1999).  In terms of sperm related content, induction of O-
GlcNAcylation possibly blocks or inhibits the phosphorylation of “some” PKA 
substrates, causing significantly impaired hyperactivation. I mention “some” substrates 
because one the one hand, one PTM antagonizes the other and on the other hand 
Tyrosine phosphorylation is increased during induction of O-GlcNAcylation and it is 
known that Tyrosine phosphorylation increase is a result of a protein kinase cascade 
downstream of PKA. 
Another way that possibly O-GlcNAc effects sperm capacitation is through the 
proteasome itself. As I discussed in chapter 1.9.7, O-GlcNAc is involved by two 
different ways in the degradation process. First by altering the targeting of some 
proteins to the proteasome and secondly by altering the activity of the proteasome itself. 
Kong et al. demonstrated that proteasome plays a huge role in mammalian 
capacitation(Kong et al., 2009). By incubating highly motile sperm with proteasome 
inhibitors they inhibited capacitation and they also changed the pattern of tyrosine 
phosphorylation. This fact suggests the importance of the proteasome in regulating 
protein phosphorylation patterns during capacitation by possibly by degrading specific 
kinases that are not needed. Since O-GlcNAc regulates the proteasome itself, it is 
possible that O-GlcNAcylation possibly regulates the presence or absence of specific 
kinases during the capacitation process through the O-GlcNAcylation status of the 
proteasome. 
More work needs to be done, in order to completely elucidate the signalling pathways 
responsible for the induction of sperm hyper-activation. Hopefully we will get better, in 
the understanding of the nature of this complex biochemical process that renders 
spermatozoa able to fertilize. The better understanding will allow us to develop drugs to 
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treat male infertility and diminish the need of consistently resorting to ART, which are 
expensive and invasive.    
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Appendix 
1 Role of O-GlcNAc modification in embryonic stem cells 
Mouse embryonic Stem Cells (MESCs) are derived from the inner cell mass of the 
blastocyst and have the ability to self-renew and differentiate into all types of 3 
embryonic germ layers (endoderm, mesoderm, ectoderm). These 3germ layers give rise 
to more than 220 cell types in the adult body including germ cells. The understanding of 
their function will allow us to alter the way people are being treated. Their plasticity and 
their unlimited capacity for self-renewal promote them as perfect candidates for cell 
replacementtherapies and especially treatment of male infertility. Male factor infertility 
is identified in almost 50% of infertile couples while it is the sole cause in 20-30% of 
infertile couples. However, the signalling pathways that control cell-fate are vast and 
hugely complex. Inside the cell numerous post-translational modifications take place, 
but the discovery of O-GlcNAc on cytoplasmic proteins attracted our interest. Therefore 
this part of my project is about the investigation of O-linked Acetylglucosaminated 
proteins in several of the key signalling pathways implicated in stem cell proliferation, 
cell viability and Self Renewal.  
1.1 Derivation of human and mouse ES cells 
The majority of human embryos come from the surplus of embryos that In Vitro 
Fertilization (IVF) generates. During this process multiple embryos are produced. The 
most suitable according to morphological criteria are kept for implantation into the 
patient and the rest of them can be donated for research with the absolute consent of the 
parents. The embryos are cultured until they reach the blastocyst stage. For human this 
period is 4-5 days post fertilization, at which time the human blastocyst consists of 50-
150 cells. The inner cell mass (ICM) is separated from the trophoectoderm, which is 
responsible for the formation of extra-embryonic tissue, with Immunosurgery. In 
Immunosurgery the cells of trophoectoderm are destroyed by brief exposure to 
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antibodies directed against human cell in tandem with complement activity (Chen and 
Melton, 2007). The remaining inner cell mass is plated onto cells that will supply 
support. Expansion of the inner cell mass will lead to a formation of an embryonic cell 
line. The cells must be separated every 4-7 days and they can retain their pluripotency 
even after months of proliferation. In mice, the ES cells are derived from the inner cell 
mass of the embryo, which is harvested from the donor-mother animal by following 
similar techniques. 
1.2 Self-renewal and signalling pathways controlling self-renewal 
Self-renewal is the ability of the cell to renew itself indefinitely, while maintaining the 
undifferentiated state. This process requires cell cycle control and involves complex 
networks. These networks are regulated by cell extrinsic signals from the 
microenvironment of the stem cell. We try to elucidate the mechanisms that are 
responsible for this process. 
1.3 The LIF Pathway 
The first mouse embryonic stem cells were cultured on mouse embryonic fibroblasts 
(MEF). The need for this feeder layer was negated by the addition of conditioned media 
from buffalo rat liver cells(BRLs) directly to mESC cultures. The media contained an 
IL-6 family cytokine that inhibits ES cell differentiation. After its secretion LIF binds to 
a heteromeric complex, which consists of gp130 and LIF receptor, and activates Janus 
Kinase (JAK). JAK phosphorylates STAT proteins (STAT1 and STAT3) and activates 
them. STAT3 relocates to the nucleus as a homodimer and activates c-Myc, which is a 
transcription factor responsible for cell self-renewal. LIF by itself cannot promote self-
renewal but it requires the presence of BMP-4 or serum. Secreted BMP-4 binds to a 
tetra-dimeric complex that forms BMP-4 membrane receptor and triggers the 
phosphorylation of R-Smad (Receptor Regulated Smad (R-Smad: Smad1,5 and 8) 
proteins. Activated R-Smad proteins form a complex with co-Smad (Smad4), and the  
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complex translocate into the nucleus to regulate target gene expression (Datto and 
Wang, 2000). They induce the expression of inhibitor of differentiation (Id). Id protein 
has a very important role in cell fate determination. If Id protein is overexpressed in 
mouse ES cells, LIF is able to maintain self-renewal of ES cells even with the absence 
of BMP-4 (Ying et al., 2003, Fei and Chen, 2010). BMP has been also reported, to be 
implicated in several lineage commitment pathways (Seuntjens et al., 2009). 
LIF through its receptor gp130 has the ability to activate ERK (Niwa et al., 1998, 
Burdon et al., 1999). Activation of the BMP pathway causes the induction of dual-
specificity phosphatase 9 (DUSP9). DUSP9 is an ERK-specific phosphatase. So BMP 
helps mouse ESCs maintain their self-renewal state by inhibiting the stimulating effect 
of LIF and FGF4 signalling on ERK activity. The mechanistic background behind the 
inhibitory effect consists of a Smad-dependent up-regulation of DUSP9. It is also 
proposed that DUSP9 can substitute BMP4 to sustain ESC Self-Renewal when 
combined with LIF (Li et al., 2012). 
1.4 Other factors that induce self-renewal 
Nichols showed that LIF receptor gp130 -/- mouse can develop to a post the blastocyst 
stage, suggesting that additional factors may also be involved in maintaining pluripotent 
cells in vivo (Nichols et al., 2001). In 2003 a new homeobox transcription factor 
(Nanog) was discovered which is specifically expressed in ES cells. Mouse Nanog 
protein consists of 280 amino acids and contains a homeobox domain (Homeobox genes 
encode transcription factors that typically switch on cascades of other genes). It consists 
of three domains. A C-terminal, a N-terminal and a homeodomain but only C-terminal 
exhibits high trans-activator function, suggesting that only C-terminal domain is 
functionally dominant. C-terminal also has a highly conserved 10 pentapeptide repeat 
(WR). Nanog has the ability to promote stem cell self-renewal and pluripotency. 
Deletion of the Nanog gene results in loss of pluripotency in both ICM (Inner Cell 
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Mass) and ES cells (Mitsui et al., 2003). The above distinct abilities come as a result of 
a LIF-independent transcription factor network, as overexpression of Nanog does not 
lead to the activation of STAT3. A lot of evidence indicates that Nanog functions 
through an independent pathway of Stat3. CAG-elevated ES cells show no increase in 
phosphorylation kinetics of Stat3. Secondly inactivation of Stat 3 pathway via LIF 
depletion leads to the formation of a different phenotype in comparison with Nanog null 
cells. Finally addition of LIF to CAG-Nanog cell culture enhances growth of ES cells 
[50]. Also addition of Janus-kinase inhibitors does not affect Nanog levels.  
Nanog is not acting alone to maintain pluripotency. Along with other key regulatory 
pluripotent factors such as Oct4 and Sox2, form a regulatory network to support or limit 
each other’s expression level.   Nanog and Oct4 are homeodomain proteins and Sox2 is 
a High-Mobility Group factor (High-Mobility Group or HMG proteins are 
chromosomal proteins with main aim to help with transcription, replication, 
recombination and DNA repair). Oct4/ Sox2 bind to the Nanog promoter in vitro and in 
vivo and promote Nanog transcription in pluripotent cells (Rodda et al., 2005).  
However Oct4 deficient mice embryos express Nanog suggesting that also other 
pluripotency factors contribute to the regulation of Nanog expression. Reporter assays 
reveal that FoxD3, a forkhead family transcription factor, can activate the Nanog 
promoter. Chromatin immuno-precipitation (ChIP) assays confirm the ability of FoxD3 
to bind Nanog promoter region in vivo (Pan et al., 2006). Except FoxD3 recent evidence 
shows that also the tumour suppressor gene, p53, can bind to the Nanog promoter in 
vivo and in vitro. Finally treatment of p53 -/- ES cells with retinoic acid (RA) during 
the differentiation still keeps Nanog down regulated, fact that suggests that other 
negative regulator factors are involved in suppressing Nanog during ES cell 
differentiation (Lin et al. (2005). 
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1.5 Canonical Wnt signalling in ESC self-renewal 
B-Catenin is a protein that in humans is encoded by the CTNNB1 gene, and is the core 
component of the canonical Wnt pathway. When the Wnt ligands are absent, β-catenin 
gets phosphorylated by GSK3 and subsequently degraded by proteolysis. When the Wnt 
ligands are present, they bind with β-catenin, preventing its degradation. Accumulated 
hypo-phosphorylated β-catenin enters nucleus causing the up regulating of Stat3 
mRNA.  
1.6 Signalling pathways controlling differentiation 
Fibroblast Growth Factors (FGFs) and their receptors (tyrosine kinases) play an 
important role in regulating pluripotency and lineage segregation in pluripotent 
mammalian stem cells. Binding of the ligand to the receptor results in the auto-
phosphorylation of tyrosine residues in the intracellular region of an FGF receptor 
(FGFR). The signal is further relayed through four distinct pathways: the Janus 
kinase/signal transducer and activator of transcription (Jak/Stat), phospho-inositide 
phospholipase C (PLCg), phosphatidylinositol 3- kinase (PI3K) and Erk pathways.  
5.1.7 Therapeutic potential in male infertility 
One day, men who lose the ability to produce sperm after chemotherapymay be able to 
regain their fertility because of stem cells. Men possess spermatogonial stem cells, that 
have the ability to produce spermatozoa and can be frozen before any exposure of the 
patient to therapeutic agents. A few months after the cancer treatment the stem cells can 
be re-injected back to patient testis and re-establish sperm production.   
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2 Materials and Methods 
2.1 Materials 
1. Proliferation Media Components: 
• GMEM (Glasgow Modified Eagles Media)(500ml)(Life Technologies): 
It contains a combination of amino acids, salts (calcium chloride, 
potassium chloride, magnesium sulphate, sodium chloride and 
monosodium phosphate), glucose and vitamins (folic acid, nicotinamide, 
riboflavin, B12). It also contains iron and phenol red. Phenol red is used 
as pH indicator, which helps in monitoring the changes of the pH in the 
cell culture. When the pH becomes acidic (below 6.8), then the colour of 
the media changes from red to yellow. 
• Fetal Bovine Serum (FBS)(50ml): Induction of coagulation is followed 
by conversion of fibrinogen to fibrin, which leads to the formation of a 
blood clot. The portion of plasma remaining after coagulation is the FBS. 
FBS contains a rich variety of proteins and growth factors, which support 
the proliferation of the cells.  
• Sodium Pyruvate 100x (5ml)(GIBCO-Invitrogen): Sodium pyruvate is 
added to cell culture because it is an anti-oxidant, so it provides an 
effective layer of protection against hydrogen peroxide (Giandomenico 
et al., 1997) but it is also an additional source of energy along with the 
utilisation of glucose because it participates in the production of the high 
energy intermediate ATP within the cells. 
•  MEM Non-Essential Amino Acids (NEAA) (5ml) (GIBCO-Invitrogen): 
Addition of Non-Essential Amino Acids to medium improves growth 
and viability of propagating cell in the culture. 
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• Mercaptoethanol (3,5μL): is a potent reducing agent used in cell culture 
medium to prevent toxic levels of oxygen radicals. 
• Leukaemia Inhibitory Factor (LIF) (1/1000): LIF is an interleukin 6 
family cytokine. Addition of LIF in to the culture media inhibits ES cell 
differentiation by STAT3 pathway. 
2. Differentiation Media (N2B27):  
• Neurobasal Media (250ml) (Invitrogen) 
• DMEM-F12 (250ml) (Invitrogen)  
• N2 supplement (2.5ml): N2 is a serum-free supplement and is suitable 
for the growth, survival and expression of post-mitotic neurons.  
• B27 supplement (5ml): B27 is a serum-free supplement that is used 
along with Neurobasal and supports the growth and viability of neurons. 
• Glutamine (5ml) 
• Mercaptoethanol (3.5μl)  
3. Dulbecco’s Phosphate Buffered Saline (dPBS): It’s a isotonic buffer system 
intended to provide maintenance of the pH of the cell culture in to the 
physiological range of 7.2-7.6 and at the same time provides cells with water 
and certain bulk of inorganic ions which are essential for normal cell 
metabolism. When it is combined with carbohydrates, such as glucose, which 
serve as energy sources, dPBS can sustain the viability of the cells for a limited 
period of time. 
4. DMSO (1mΜ): vehicle control  
5. GlcNAcstatin (1μΜ): GlcNAcstatin binds directly to the active site of OGA by 
hydrogen bonding and blocks it. The above reaction results in increased O-
GlcNAc levels. 
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6. GalNacstatin (1μΜ):GalNacstatin is an inactive isomer of GlcNAcstatin. It does 
not inhibit OGA but is structurally similar to GlcNAcstatin. This means any 
effects seen in GlcNAcstatin treatment can be more confidently attributed to 
OGA inhibition, rather than off-target effects. 
7. Thiamet G (1μΜ): An OGA inhibitor structurally unrelated to GlcNAcstatin 
2.2 Methods 
 
1. Cell Culture: Cell culture flasks (Corning, Sigma Aldrich) were coated with 
10ml of gelatine for 20 minutes at 37o C to ensure adherence to the flask. 
Gelatine was aspirated using a glass Pasteur pipette and 10ml of GMEM+LIF 
(for maintenance) containing approximately 1million cells from 46C cell line 
were added in the flask. After ±48h of cell culture, cells reached 80% confluence 
and the cells had to be re-plated in a new flask. Old media was aspirated using a 
glass Pasteur pipette and the cells were gently washed with 10ml of dPBS 
(1minute each wash). 1ml of Accutase was added directly to the cells and the 
flask was agitated until the cells came to a single cell suspension state, as 
evaluated by light microscopy. Media was then added to the cell suspension by 
gently pipetting up and down in order to remove any remaining cells stuck on to 
the flask surface. The suspension was then transferred in a 15ml Falcon tube and 
centrifuged at 800g for 5 minutes. After the end of centrifugation, the excess 
media was carefully aspirated and the pellet was re-suspended in 10ml of fresh 
media. The concentration of the cells in the suspension was calculated with a 
haemocytometer. The appropriate amount of cell suspension containing 1million 
cells was transferred into a new flask and media was added until the total 
volume was 10 ml (25cm2 Flask) or 20ml (25cm2 Flask).  
2. Alkaline Phosphatase (AP) staining of cells with Sigma Kit 
Protocol described in the kit provided. 
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3. Western Blotting: Described in chapter 2 
4. Counting Protocol: To prepare the haemocytometer, the surface is carefully 
cleaned with ethanol and the coverslip is placed over the counting surface before 
adding the cell suspension. A small volume of cell containing media is pipetted 
onto a haemocytometer. Enough volume should be pipetted, in order to cover 
the whole surface. Cell suspensions should be dilute enough, so that the cells do 
not overlap each other on the grid. Also, before a sample is taken, the cell 
suspension is thoroughly mixed, so that the sample will be representative. The 
haemocytometer is then placed under the microscope. The grid contains 9 large 
squares. Each square has a surface of 1mm2 and the depth of the chamber is 
0.1mm. So each square represents a volume of 0.1mm3. 1ml is 1mm3 and 
according to that we can calculate the total number of cells in the cell 
suspension. 
5. Lactate Dehydrogenase  (LDH) assay: LDH is a soluble cytosolic enzyme 
present in most eukaryotic cells. Toxic compounds lead to the release of LDH in 
the culture medium, due to damage of plasma membrane. Since LDH is a fairly 
stable enzyme, has been widely used to evaluate the presence of damage and 
toxicity of tissue and cells. The increase of the LDH in the concentration of a 
culture’s supernatant is proportional to the number of lysed cells. The assay used 
here provides a photometric method to measure LDH activity. The reaction 
velocity is determined by measuring the decrease in absorbance resulting from 
the oxidation of NADH.  NADH+pyruvate lactate+NAD-. In each well 10μL 
of sample + 840μL Imidazole + 10μL DTT + 100μL NADH. The plate is 
carefully mixed. At last 50mL of pyruvate (substrate) are added in each well and 
the plate is placed into the photometer to measure the absorbance of the sample. 
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3 Results 
3.1 Western GNS 
To confirm that the known effects of GlcNAcstatin are applicable to ES cells, cells were 
plated in GMEM + serum + LIF + GNS, and at the time points stated in Figure 3-1. 
Samples were lysed and equalised for Western Blotting according to the described 
protocol. 
 
 
Figure 3-1: Western blot analysis for O-GlcNAc levels after adding GNS in the cell culture (Time points: 0min, 
5min, 15min, 30min, 1h, 2h, 4h, 8h, 24h) 
Figure 3-1 displays multiple bands (representing O-GlcNAcylated proteins) with 
increasing density as cells are incubated for longer periods of time with the inhibitor 
(GNS). GNS blocks OGA. OGA inhibition causes a marked increase in global O-
GlcNAc levels. 
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3.2 Growth Curves 
To examine the effects of OGA inhibition in the proliferating capacity of the ES cells, a 
seven-day time course experiment was performed. Every 24 hours the concentration and 
the number of total cells were calculated. As control, a biologically inactive isomer of 
GNS was used (GLS) along with a second O-GlcNAc inhibitor (Thiamet G).  
Figure 3-2: 7-Day time course experiment examining the effects of OGA inhibitors in cell proliferation. 
Examination of the graph reveals no effects on cell proliferation even after prolonged 
treatment with GNS. 
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3.3 Cell viability 
In order to estimate possible toxic effects of GNS after prolonged treatment with the 
cells, a LDH assay was used to measure the enzymatic activity of the entire population 
of cells. No significant differences were observed (Figure 3-3).   
 
Figure 3-3: LDH assay in order to investigate possible toxic effects of GNS 
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3.4 Scores Alkaline phosphatase is a phenotypic marker of pluripotent stem cells. While is expressed in most cell types, its expression is highly elevated in pluripotent stem cells. In the present experiment, we compare the effect of various media (media with or without GNS in the presence or absence of LIF) in the differentiating capacity of the cells. 
 
Figure 3-4: Cells cultures were treated with combination of three different compounds examining if inducing 
O-GlcNAcylation in presence or absence of LIF affects ES cell self-renewal. 
 
Our results demonstrate that ES cell differentiation remains unaffected under conditions 
of increased O-GlcNAc signalling 
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3 Discussion In the final part of the project we examine the effects of the induction of O-GlcNAcylation in stem cells. Stem cells have the ability to self-renew and they have huge developmental capacity. Their differentiation is controlled by the interaction of multiple signalling pathways. These signalling pathways are typically mediated by post-translational modifications. O-GlcNAcylation is one such modification, which although regulates the function of several proteins, little is known about it’s effects in stem cells. Our experiments prove that induction of O-GlcNAcylation has no effects in cell viability or proliferation even after prolonged treatment. This comes in contrast with latest data suggesting, that O-GlcNAc signaling causes a differentiation deficiency in serum-free monolayer conditions.These data suggest that O-GlcNAc signaling stimulates Wnt transcriptional activity by up-regulating the transcriptional activator Lef1 leading to reduced entry of ES cells into a differentiated state.   
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4 Additional motility data – frequency distributions 
Motility frequency distributions, provide an arrangement of the values that each motility 
variable takes in a sample. So in addition to the information extracted from the average 
values presented in Chapter 4, frequency distribution can sometimes provide additional 
information. In the experiments conducted, no additional information could be 
extracted, as in most cases, no significant differences in the distribution of the 
population, were observed. 
 
Inhibitor 1: GlcNAcstatin (GNS) 
 
 
 
 
Influence of O-GlcNAcylation induction (GNS treatment) on human sperm path 
velocity. Values are mean ±SEM for 10 individual donor ejaculates  
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Influence of O-GlcNAcylation induction (GNS treatment) on human sperm progressive 
velocity. Values are mean ±SEM for 10 individual donor ejaculates. 
 
Influence of O-GlcNAcylation induction (GNS treatment) on human sperm linearity 
(LIN). LIN can be calculated from two individual velocity parameters, straight line 
velocity (VSL) and curvilinear velocity (VCL). Values are mean plus or minus SEM for 
10 individual donors. 
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Influence of O-GlcNAcylation induction (GNS treatment) on human sperm Amplitude 
of lateral head displacement (ALH). Values are mean plus or minus SEM for 10 
individual donor ejaculates.    
Influence of O-GlcNAcylation induction (GNS treatment) on human sperm curvilinear 
velocity (VCL). Values are mean ±SEM for 10 individual donor ejaculates.  
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Influence of O-GlcNAcylation induction (GNS treatment) on Beat Cross Frequency. 
Values are mean ±SEM for 10 individual donor ejaculates. 
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Inhibitor 2: Thiamet G 
Influence of O-GlcNAcylation induction (Thiamet G) on human sperm path velocity. 
Values are mean ±SEM for 7 individual donor ejaculates. 
 
Influence of O-GlcNAcylation induction (Thiamet G) on human sperm progressive 
velocity. Values are mean ±SEM for 7 individual donor ejaculates 
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Influence of O-GlcNAcylation induction (Thiamet G) on human sperm linearity (LIN). 
LIN can be calculated from two individual velocity parameters, straight line velocity 
(VSL) and curvilinear velocity (VCL). Values are mean plus or minus SEM for 7 
individual donors. 
 
 
Influence of O-GlcNAcylation induction (Thiamet G) on human sperm Amplitude of 
lateral head displacement (ALH). Values are mean plus or minus SEM for 7 individual 
donor ejaculates. 
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Influence of O-GlcNAcylation induction (Thiamet G) on human sperm curvilinear 
velocity (VCL). Values are mean ±SEM for 7 individual donor ejaculates. 
 
 
 
 
Influence of O-GlcNAcylation induction (Thiamet G) on Beat Cross Frequency. Values 
are mean ±SEM for 7 individual donor ejaculates. 
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Inhibitor 3: PUGNAc 
Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm path 
velocity. Values are mean ±SEM for 7 individual donor ejaculates. 
 
Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm 
progressive velocity. Values are mean ±SEM for 7 individual donor ejaculates. 
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Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm 
linearity (LIN). LIN can be calculated from two individual velocity parameters, straight 
line velocity (VSL) and curvilinear velocity (VCL). Values are mean plus or minus 
SEM for 7 individual donors. 
 
 
Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm 
Amplitude of lateral head displacement (ALH). Values are mean plus or minus SEM for 
7 individual donor ejaculates. 
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Influence of O-GlcNAcylation induction (PUGNAc treatment) on human sperm 
curvilinear velocity (VCL). Values are mean ±SEM for 7 individual donor ejaculates.  
 
 
 
 
 
Influence of O-GlcNAcylation induction (PUGNAc treatment) on Beat Cross 
Frequency. Values are mean ±SEM for 7 individual donor ejaculates. 
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Inhibitor 4: 4Ac5S-GlcNAc 
 
 
 Influence of 4Ac5S-GlcNAc treatment (OGT inhibition) on human sperm path 
velocity. Values are mean ±SEM for 7 individual donor ejaculates. 
Influence of 4Ac5S-GlcNAc treatment (OGT inhibition) on human sperm progressive 
velocity. Values are mean ±SEM for 7 individual donor ejaculates. 
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Influence of O-GlcNAcylation induction (4Ac5S-GlcNAc treatment) on human sperm 
linearity (LIN). LIN can be calculated from two individual velocity parameters, straight 
line velocity (VSL) and curvilinear velocity (VCL). Values are mean plus or minus 
SEM for 7 individual donors. 
 
 
Influence of 4Ac5S-GlcNAc treatment (OGT inhibition) on human sperm Amplitude of 
lateral head displacement (ALH). Values are mean plus or minus SEM for 7 individual 
donor ejaculates. 
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Influence of 4Ac5S-GlcNAc treatment (OGT inhibition) on human sperm curvilinear 
velocity (VCL). Values are mean ±SEM for 7 individual donor ejaculates.  
 
 
 Influence of 4Ac5S-GlcNAc treatment (OGT inhibition) on Beat Cross Frequency. 
Values are mean ±SEM for 7 individual donor ejaculates 
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